Protocol J1X- MC-GZHC (c)  
 
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple- Ascending Subcutaneous Doses of LY3493269 in Patients with Type 2 Diabetes Mellitus  
[STUDY_ID_REMOVED] 
Approval Date: 16-Jul-2021 
C O N FI D E N TI A L Pr ot oc ol  J 1 X -M C -G Z H C ( c) 
1Title P a ge 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of cli ni c al i n v e sti g at or s. It i s t h e pr o p ert y of 
Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al 
i n v e sti g ati o n of L Y 3 4 9 3 2 6 9 , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y a n d C o m p a n y or it s 
s u b si di ari e s . 
N ot e t o R e g ul at or y A ut h oriti e s: T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a a n d/ or c o m m er ci all y c o nfi d e nti al i nf or m ati o n 
e x e m pt fr o m p u bli c di s cl o s ur e. Eli Lill y a n d C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y p u bli c r e l e a s e. 
I n t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) E x e m pti o n 4 a n d m a y n ot b e r e pr o d u c e d or 
ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s .
Pr ot oc ol Title: S af et y,  T o lera bilit y,  P h ar m a c o ki n eti cs, a n d P har mac o d y na mics of M ult i p le -
Asce n di n g S u bc uta ne o us D oses of L Y 3 4 9 3 2 6 9 i n Patie nts wit h T y pe 2 Di a betes 
Mellit us 
Pr ot oc ol N u m ber: J 1 X -M C -G Z H C 
A me n d me nt N u m ber: c
C o m p o u n d :L Y [ADDRESS_1258651] u d y P h ase: 1
S h ort Title: M ul ti ple -Asce n di n g D ose St u d y  of  L Y 3 4 9 3 2 6 9 A d mi nistere d S u bc uta ne o usl y 
S p o ns or N a me: El i Lill y  a n d C o m pa n y 
Le g al Re gistere d A d dress: I n dia na p o lis, I n dia na ,U S A 4 6 2 8 5 
Re g ul at or y A ge nc y I de ntifier N u m ber: I N D 1 4 8 2 7 8 
A p pr o v al D ate :
Pr ot oc ol  A me n d me nt ( c) El e ctr o ni call y  Si g ne d a n d A p pr o ve d b y  Lill y  o n date pr o vi de d bel o w. 
A p pr o v al D at e: 1 6- J ul- 2 0 2 1 G M T 
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
2Medical Monitor Name [CONTACT_9352] [CONTACT_17055] .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment ( b) 13-Oct ober-2020
Amendment (a) 11-July -2020
Original Protocol 27-May -2020
Amendmen t [c] 
This amendment is considered to be nonsubstant ial.
Overall Rationale for the Amendment:
Thisamendment serves to clarify that all samples collected for determination of acetaminophen 
concentrations (as a pharmacodynamic marker for gastric empt ying) must be analy zed, 
regardl ess of the treatm ent assi gned to the tri al parti cipant .
Section # and 
NameDescription of Change Brief Rationale
[IP_ADDRESS] . 
Bioanalysis of 
AcetaminophenRemoved the sentence 
“Analysis of samples collected 
from placebo treated 
participants are not pl anned”The statem ent was rem oved as all 
samples collected for PD m arkers must 
be analy zed.
9.4.4 . 
Pharmacodynamic 
AnalysisAdded placebo in the sentence 
“Baseline -adjusted C maxof 
acetaminophen (ratio to Day  -1 
value) will be calculated and 
log transform ed to com pare the 
gastri c-empt ying effect of 
LY3493269 to that of 
dulaglut ide and pl acebo ”Toclarify that data from placebo -
treated participants will also be 
analy zed.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
4Table of Contents
1. Protocol Summary ...................................................................................................... [ADDRESS_1258652] ivities (SoA) ...................................................................................... 10
2. Introduction .............................................................................................................. 17
2.1. Study  Rati onale .......................................................................................................... 17
2.2. Backgro und................................................................................................................ 17
2.2.1. Summary  of Clinical Experience ................................................................................ 18
2.3. Benefit/Risk Assessment ............................................................................................ 19
3. Objectives and Endpoints ......................................................................................... 20
4. Study Design ............................................................................................................. 22
4.1. Overall Design ............................................................................................................ 22
4.1.1. Screeni ng Peri od......................................................................................................... 23
4.1.2. Baseline Period ........................................................................................................... 23
4.1.3. Treatment Period ........................................................................................................ 23
4.1.4. Follow-up Peri od........................................................................................................ 24
4.2. Scientific Rationale for Study  Design ......................................................................... 24
4.2.1. Parti cipant Input into Desi gn...................................................................................... 25
4.3. Justification for Dose .................................................................................................. 25
4.4. End of Study  Definit ion.............................................................................................. 28
5. Study Population ...................................................................................................... 29
5.1. Inclusio n Cri teria........................................................................................................ 29
5.2. Exclusio n Cri teria....................................................................................................... 30
5.3. Lifes tyle Considerat ions............................................................................................. 33
5.3.1. Meals and Dietary  Restri ctions................................................................................... 33
5.3.2. Caffeine, Alcoho l, and Tobacco .................................................................................. 33
5.3.3. Activity...................................................................................................................... 34
5.4. Screen Failur es........................................................................................................... 34
6. Study Intervention .................................................................................................... 35
6.1. Study  Intervent ions Administered ............................................................................... 35
6.1.1. Administrati on Details ................................................................................................ 35
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 35
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 36
6.4. Study  Intervent ion Compliance ................................................................................... 37
6.5. Concomitant Therapy .................................................................................................37
6.6. Dose Modificat ion...................................................................................................... 38
6.6.1. Dose Escal ation.......................................................................................................... 39
6.6.2. Dose -Escal ation Stoppi[INVESTIGATOR_2121] .............................................................................. 39
6.6.3. Data Review during the Study .................................................................................... 40
6.7. Intervention after the End of the Study ........................................................................ 40
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 41
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
57.1. Discontinuati on of  Study  Intervent ion........................................................................ 41
7.1.1. Liver Enzymes and Other Laboratory ......................................................................... 41
7.1.2. Persi stent Hy perglycemia/Hypoglycemia .................................................................... 42
7.1.3. Hypersensi tivity Reacti ons......................................................................................... 42
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. [ADDRESS_1258653] Circumference .................................................................................................. 57
8.7. Genetics..................................................................................................................... 58
8.8. Biomarkers ................................................................................................................. 58
8.9. Immunogenicit y Assessments ..................................................................................... 58
8.10. Health Economics ....................................................................................................... 59
9. Statistical Considerations ......................................................................................... 60
9.1. Statistical Hypotheses .................................................................................................60
9.2. Sample Si ze Determinat ion......................................................................................... 60
9.3. Popul ations for Analyses ............................................................................................ 61
9.4. Statistical Analyses ..................................................................................................... 61
9.4.1. General Considerations ............................................................................................... 61
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
69.4.2. Safety Analyses .......................................................................................................... 62
9.4.3. Pharmacokinet ic Analyses .......................................................................................... 63
9.4.4. Pharmacodynamic Analyses ....................................................................................... 63
9.4.5. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 64
9.4.6. Evaluat ion of Immunogenicit y.................................................................................... 64
9.5. Interim Analyses ......................................................................................................... 65
9.6. Data Monitoring Committee (DMC) ........................................................................... 65
10. Supporting Documentation and Operational Considerations ................................ 66
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 66
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 66
10.1.2. Inform ed Consent Process .......................................................................................... 66
10.1.3. Data Protection ........................................................................................................... 67
10.1.4. Disseminat ion of Clinical Study  Data ......................................................................... 67
10.1.5. Data Qualit y Assurance .............................................................................................. 68
10.1.6. Source Documents ...................................................................................................... 69
10.1.7. Study  and Si te Start and Cl osure ................................................................................. 69
10.1.8. Publicat ion Policy ....................................................................................................... 70
10.1.9. Long -Term  Sample Retent ion..................................................................................... 70
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 71
10.2.1. Blood Sam pling Summary .......................................................................................... 74
10.3. Appendix 3: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 76
10.3.1. Definit ion of AE......................................................................................................... 76
10.3.2. Definit ion of SAE ....................................................................................................... 77
10.3.3. Recording and Fo llow-Up of AE and/or SAE ............................................................. 78
10.3.4. Reporting of SAEs ...................................................................................................... 80
10.3.5. Sponsor Surveillance Process for Dose Escalat ion or Cohort 
Expansio n................................................................................................................... 80
10.4. Appendix 4: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... [ADDRESS_1258654] ion of Pregnancy  Information.......................................................................... 83
10.5. Appendix 5: Genetics .................................................................................................85
10.6. Appendix 6: Liver Safet y: Suggested Actions and Follow -up 
Assessments ............................................................................................................... 86
10.7. Appendix 7: Pancreat ic Monitoring ............................................................................ 88
10.8. Appendix 8: Hy persensi tivity Event Tests .................................................................. 90
10.9. Appendix 9: Abbreviat ions......................................................................................... 91
10.10. Appendix 10: Protocol Amendment History ............................................................... 95
11. References ................................................................................................................. 98
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
71. Protocol Summary
1.1. Synopsis
Protocol Title: Safety, Tolerabili ty, Pharm acokineti cs, and Pharmacodynamics of Mult iple-
Ascending Subcutaneous Doses of LY3493269 in Patients with Ty pe 2 Diabetes Mellitus
Short Title: Multiple-Ascending Dose Study  of LY3493269 Administered Subcutaneously
Rationale :
LY3493269 is a dual glucose -dependent insulinotropic polypeptide and glucagon -like-pepti de 1 
(GLP -1)receptor agonist being developed as a trea tment for type 2 di abetes mellitus ( T2DM ) .
This is the first study  in participants withT2DM to test mult iple subcutaneous ( SC)doses of 
LY3493269 to establish early exposure -responses for key  efficacy, safet y, and tol erabili ty 
relationships ( for example, blood glucose, glycated hemoglobin ). Using a stepwise escalat ion, it 
is planned that this study  will test dose l evels higher than those tested in the single- ascending 
dose study .
Study  J1X-MC-GZHC ( GZHC )will invest igate the safet y, tolerabili ty, pharm acokinetics , and 
pharmacodynamics ( PD)of LY3493269 administered as 4 once -weekly SC doses in patients 
with T2DM. Trulicit y®(dulaglut ide) will be used as a posit ive control for PD of GLP -1 
pharmaco logy.
Objectives and Endpoint s
Objectives Endpoints
Primary
To investigate the safety and tolerability of 
LY3493269 following 4 once -weekly SC dosesTEAEs and SAEs
Secondary
To characterize the PK of LY3493269 following 
4 once -weekly SC dosesCmaxand AUC
To evaluate the change in FG following 4 once -
weekly SC doses of LY3493269 and dulaglutideChange f rom baseline in FG
Abbreviations: AUC = area under the concentration versus time curve; C max= maximum observed drug 
concentration; FG = fasting glucose; PD = pharmacodynamic s; PK = pharmacokinetic s; SC = subcutaneous; 
TEAE = treatment -emergent adverse event; SAE = serious adverse event.
Overall Design
Study  GZHC is a Phase 1, multicenter, randomized, investigator -and participant -blind, placebo -
controlled, comparator -controlled, 4 -week mult iple-dose escala tion study  in pat ients with T2DM.
Disclosure Statement :This is a m ultiple-dose escal ation study  that i s invest igator -and 
participant -blind.
Number of Participant s:
Approximately  64 parti cipants m ay be rando mly assigned to study  intervent ion such that 
approximately 12 evaluable participants fro m each of the 4 cohorts complete the study .If 
participants are discont inued during the study, additional participants may be enrolled to 
complete the target number of evaluable part icipants .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
8Intervention Groups and Duration :
Eligible participants will be rando mly assigned to study  interventi on:
8 to LY3493269
2 to dul aglut ide, and
2to placebo.
Each participant’s invo lvement in the study  is expected to last up to 1 6weeks, including a
6-week screening period
1-week baseline period
4-week treatment period, and 
a minimum [ADDRESS_1258655] dose.
Data Monitoring Committee: No
C O N FI D E N TI A L Pr ot oc ol  J 1 X -M C -G Z H C ( c) 
91. 2. Sc he m a 
A b bre viati o n: F U = f oll o w - u p. 
N ote: T he i nitiati o n of eac h co h ort will be sc he d ule d s uc h t hat apla n ne d escalate d d ose ( i n b ol d gr a y circle s) is 
s u p p orte d b y a re vie w of 2 -wee k safet y a n d t olera bilit y data fr o m t he prece di n g l o wer d ose ( i n dicate d b y b ol d 
vertical gr a y li nes). Partici pa nts i n C o h orts [ADDRESS_1258656] u d y J 1 X -M C -G Z H C .C CI 
C CI 
C CI 
C CI 
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
101.3. Schedule of Activities (SoA)
Study Schedule for Cohorts 1 and 2
Procedure
ScreeningBaseline Treatment (Cohorts 1 and 2) FU Comments
Visit # 1 2 3 4 5 6 7 8 9 10E
D
Days
-42 to -4
−3
−2
−1
1
2
3
4
5
7 ±1
8 ±1
12 ±1
14 ±1
15 ±1 18 ±1
21
22
23
24
25
26
28 ±1
29
30
36 ±2
57 ±7
Informed consent X
Drug/alcohol screen
(local lab oratory
throughout)X X X XPer s ite policy or 
investigator’s 
discretio nduring 
the study .
Admission to siteX*X X*May occur on
Day -
[ADDRESS_1258657] 
circumferenceX X P P P X XXX
Body temperature X XX P X
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
11Procedure
ScreeningBaseline Treatment (Cohorts 1 and 2) FU Comments
Visit # 1 2 3 4 5 6 7 8 9 10E
D
Days
-42 to -4
−3
−2
−1
1
2
3
4
5
7 ±1
8 ±1
12 ±1
14 ±1
15 ±1 18 ±1
21
22
23
24
25
26
28 ±1
29
30
36 ±2
57 ±7
Vital signs –BP/HR
(h)X XXP, 1, 4, 
6, 1224 48 72 X P PP, 
6, 1224 48 XXXXX
ECG – single (h) X X XXX
ECG –triplicate (h)-0.5, 
-0.25, 
P, 1, 4, 
6, 1224 48 72 X P PP, 
6, 1224 48 XX
PK sampling (h)P, 
6, 1224 48 72 96 P PP, 
6, 1224 48 XX X XXX
Clinical laboratory 
tests -fastingX P X X P P P X XXX
Hemoglobin A1c X P X X X
AEs/concomitant 
medicationsX X XX X X X X X X X X X X X X X X X XXXXXXXX
Phone calls for 
safety monitoringX XX X
SMBG supply  
distribution , training
on self -monitoring 
and patient diariesX X X X XComplete prior to 
discharge from 
Visit 1.
Fasting plasma 
glucoseX P P P P X X X
6-point glucose X X X X X
OGTT
Glucose
Insulin
C-peptide
GlucagonX X X XSeeTable 1for 
sampling schedule .
Acetaminophen PK
for GE testX X XSee Table 1for 
sampling schedule .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
12Procedure
ScreeningBaseline Treatment (Cohorts 1 and 2) FU Comments
Visit # 1 2 3 4 5 6 7 8 9 10E
D
Days
-42 to -4
−3
−2
−1
1
2
3
4
5
7 ±1
8 ±1
12 ±1
14 ±1
15 ±1 18 ±1
21
22
23
24
25
26
28 ±1
29
30
36 ±2
57 ±7
Lipid panel , fasting
TG 
Total cholesterol
LDL -cholesterol
VLDL -cholesterol
HDL -cholesterolP X X
Satiety  VAS fasting X P P P P X
PGx sample P
Non-PGx sampl e
fasting (storage)P P P P X X
Immunogenicity P P X XX
Abbreviations: AE = adverse event; BP = blood pressure; ECG = electrocardiogram; ED = early discontinuation; FU = follow-up; GE = gastric emptying; h = 
hour; HDL = high -density lipoprotein; HR = heart rate; LDL = low -density  lipoprotein; min = minutes; OGTT = oral glucose tolerance test; 
P = predose; PD = pharmacodynamics; PGx = pharmacogenetics; PK = pharmacokinetic s; SMBG = s elf-monitored blood glucose; TG = triglyceride; VAS = 
visual analog scale; VLDL = very low -density  lipoprotein ; X = at any time during visit (for OGTT and GE test –refer to Table 1).
Table Color Code Outpatient Visit Inpatient visit Off-site activity
Notes :
Clinical laboratory tests at screening shall be analyzed at a local laboratory.All other clinical laboratory tests, PK, PD ,and biomarker samples obtained 
during the study will be analyzed at a Central Laboratory.
Where “fasting” is required, participants must have fasted for a minimum of 8 hours prior to the scheduled assessment(s).
If multiple procedures take place at the same time point, the following order of the procedure should be used: vital signs, ECG, and blood collection at 
the scheduled time point. 
Predose study assessments and procedures should be performed within 3 hours prior to planned dosing. 
Postdose assessments and procedures up to and including 24 hours should be performed within ±10% of the scheduled time. 
Postdose assessments and procedures scheduled after the 24 -hour time point should be performed within ±3 hours of the scheduled time .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
13Study Schedule for Cohorts 3 and 4
Procedure
ScreeningBaseline Treatment ( Cohorts 3 and 4 ) FU Comments
Visit # 1 2 3 4 5 6 7 8 9 10E
D
Days
-42 to -4
−3
−2
−1
1
2
3
4
5
7 ±1
8 ±1
9±1
12 ±1
14 ±1
15 ±1
16±1
18 ±1
21
22
23
24
25
26
28 ±1
29
30
36 ±2
57 ±7
Informed consent X
Drug/alcohol screen
(local laboratory 
throughout)XX X X X XPer site policy or 
investigator’s 
discretio n during 
the study .
Admission to siteX* X XX X*May occur on
Day -[ADDRESS_1258658] 
circumferenceX X P P P X XXX
Body temperature X XX P X
ECG – single (h) X X XXX
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
14Procedure
ScreeningBaseline Treatment ( Cohorts 3 and 4 ) FU Comments
Visit # 1 2 3 4 5 6 7 8 9 10E
D
Days
-42 to -4
−3
−2
−1
1
2
3
4
5
7 ±1
8 ±1
9±1
12 ±1
14 ±1
15 ±1
16±1
18 ±1
21
22
23
24
25
26
28 ±1
29
30
36 ±2
57 ±7
ECG – triplicate (h)-0.5, - 0.25, 
P, 1, 4, 6, 
12244872 XP, 1, 
4,6, 
1224P, 1, 
4, 6, 
1224P, 1, 
4,6, 
122448 XX
Vital signs –BP/HR
(h)X XXP, 1, 4, 6, 
12244872 XP, 1, 
4, 6, 
1224P, 1, 
4, 6, 
1224P, 1, 
4, 6, 
122448 XXXXX
PK sampling (h) P, 6, 12 244872 96 P, 4 P, 4P,6, 
122448XX X XXX
Clinical laboratory 
tests -fastingX P X X P P P X XXX
Hemoglobin A1c X P X X X
AEs/concomitant 
medicationsXXXX X XXX X X X X X X XX X XXXXXXXXXX
Phone calls for safety 
monitoringX X X X
SMBG supply 
distribution , training
on self -monitoring 
and pat ient diariesX X X X XComplete prior to 
discharge from 
Visit 1.
Fasting plasma 
glucoseX P P P P X X X
6-point glucose X X X X X
OGTT
Glucose
Insulin
C-peptide
GlucagonX X X XSeeTable 1for 
sampling 
schedule .
Acetaminophen PK
for GE testX X XSeeTable 1for 
sampling 
schedule .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
15Procedure
ScreeningBaseline Treatment ( Cohorts 3 and 4 ) FU Comments
Visit # 1 2 3 4 5 6 7 8 9 10E
D
Days
-42 to -4
−3
−2
−1
1
2
3
4
5
7 ±1
8 ±1
9±1
12 ±1
14 ±1
15 ±1
16±1
18 ±1
21
22
23
24
25
26
28 ±1
29
30
36 ±2
57 ±7
Lipid panel , fasting
TG
Total cholesterol
LDL-cholesterol
VLDL -cholesterol
HDL -cholesterolP X X
Satiety  VAS fasting X P P P P X
PGx sample P
Non-PGx sampl e 
fasting (storage)P P P P X X
Immunogenicity P P X XX
Abbreviations: AE = adverse event; BP = blood pressure; ECG = electrocardiogram; ED = early discontinuation; FU = follow -up; GE = gastric emptying; h = 
hour; HDL = high -density lipoprotein; HR = heart rate; LDL = low -density  lipoprotein; min = minutes; OGT T = oral glucose tolerance test; 
P = predose; PD = pharmacodynamics; PGx = pharmacogenetics; PK = pharmacokinetic s; SMBG = self -monitored blood glucose; TG = triglyceride; VAS = 
visual analog scale; VLDL = very low -density  lipoprotein ; X = at any time dur ing visit (for OGTT and GE test –refer to Table 1).
Table Color Code Outpatient Visit Inpatient visit Off-site activity
Notes :
Clinical laboratory tests at screening shall be analyzed at a local laboratory. All other clinical laboratory tests, PK, PD, and biomarker sample s obtained 
during the study will be analyzed at a Central Laboratory.
Where “fasting” is required, participants must have fasted f or a minimum of 8 hours prior to the scheduled assessment(s).
If multiple procedures take place at the same time point, the following order of the procedure should be used: vital signs, E CG, and blood collection at 
the scheduled time point. 
Predose study assessments and procedures should be performed within 3 hours prior to planned dosing. 
Postdose assessments and procedures up to and including 24 hours should be performed within ±10% of the scheduled time. 
Postdose assessments and procedures scheduled a fter the 24 -hour time point should be performed within ±3 hours of the scheduled time .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
16Table 1.Assessment Schedule for Oral Glucose Tolerance Test and Gastric Emptying 
Test
Oral Glucose Tolerance Test (OGTT) Gastric Emptying (GE) Test
Timing 
(h)aActivity OGTT samplesbTiming 
(h)cActivity Acetaminophen 
PKsamples
0dOral glucose 
solution intakeXe-0.[ADDRESS_1258659] X
Abbreviations: GE = gastric emptying; OGTT = oral glucose tolerance test; PK = pharmacokinetics.
aOGTT s ample collections are scheduled with reference to the oral glucose solution intake at time “0h”in this 
column .Sample collection sshould occur within ±10% of the scheduled time.
bAt each OGTT timepoint, samples are collected for glucose, insulin, C -peptide and glucagon.
cAcetaminophen PK sample collections are scheduled with reference to the acetaminophen solution intake at time 
“0h” in this column. Sample collections should occur within ±10% of the scheduled time.
dTime “0 h” for OGTT on Day -[ADDRESS_1258660] .
fAcetaminophen pre -
dose s ample collection . Acetaminophen PK samples and oral dose are scheduled with 
reference to acetaminophen dosing at time = 0h and approximately 30 minutes after the glucose solution intake 
for OGTT .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
172. Introduction
LY3493269 is a dual -agonist peptide that combines actions of 2 incretin hormones, glucose -
dependent insulinotropic polypept ide (GIP) and glucagon -like-peptide 1 (GLP -1). LY3493269 is 
being developed as a once -weekly  (QW)subcutaneous (SC) treatm ent for type 2 diabetes 
mellitus ( T2DM ). In addit ion, a once -daily  oral formulat ion of LY3493269 is also in 
development. 
2.1. Stud y Rationale
Study  J1X-MC-GZHC (GZHC) will invest igate the safet y, tolerabili ty, pharm acokinetics ( PK), 
and pharmacodynamics ( PD)of LY3493269 administered as [ADDRESS_1258661] m ultipleweekly SC doses of LY3493269 to establish early  
exposure -responses for key  efficacy, safet y, and tolerabilit y relationships ( for example, blood 
glucose, glycated hemoglobin [ HbA1c ]). Using a stepwise dose-escalation approach , this study  
will test dose levels higher than those invest igated in Study  J1X-MC-GZHA (GZHA ), the first -
in-human single- ascending dose ( SAD )study  of LY349326 9.
Trulicit y®(dulaglut ide) will be used as a positive control for PD of GLP -[ADDRESS_1258662] fro m GLP -1, GIP prom otes glucagon secretion at low blood glucose ( BG)
levels to augment endogenous glucose production. It stimulates lipo lysis and inhibits 
insulin -induced lipogenesis in human adipocy tes.
Glucagon -like peptide -
1is a well -characteri zed incretin horm one that potentiates insulin
secretion and reduces glucagon secret ion in a glucose -dependent manner after meal ingest ion. 
Glucagon -like peptide -[ADDRESS_1258663] ed 
receptors hi ghly expressed on islet β cells and in some non -islet cells. For example, GLP -1 
receptors ( GLP -1Rs)are expressed throughout the brain, in regio ns that control
glucose ho meostasis
gut m otility
food intake
aversive signaling, and
cardi ovascular ( CV)function (Campbell and Drucker 2013). 
C O N FI D E N TI A L Pr ot oc ol  J 1 X -M C -G Z H C ( c) 
1 8 C urre nt l y, t here are se veral a p pr o ve d G L P -1 rece pt or a g o nists ( G L P -1 R As )f o r t he treat me nt of 
di a betes a n d o besit y.  T he d osi n g of G L P -1 R As i n h u ma ns is li mite d b y  gastr oi nt esti nal ( GI )
a d verse effects, s uc h as na usea a n d v o mit i n g. 
A vaila ble precli nical a n d cli nical data i n dicate t hat c o- sti m ulat i o n of GI P a n d G L P - [ADDRESS_1258664] i m ulati o n ( C os k u n et al. 2 0 1 8; Frias et al. 2 0 1 8). 
2. 2. 1. S u m m ar y of Cli nic al E x perie nce 
St u d y  G Z H A was a first -i n -h u ma n, ra n d o mize d, place b o -c o nt r olle d, S A D st u d y  i n vest i gati n g t h e 
safet y,  t ol era bili t y ,a n d P K of L Y [ADDRESS_1258665] o p pi n g criteria were n ot m et ;h o we ver , d ue t o c o ncer ns a b o ut safet y a n d t ol era bili t y  wi t h  t he 
ne xt pla n ne d  t h e sp o ns or deci de d t o st o p f urt her d osi n g. 
No deat hs, seri o us a d verse e ve nts ( S A Es), or disc o nt i n uat i o ns d ue t o a d verse e ve nts ( A Es) were 
n ote d i n t his st u d y u p t o t he data c ut -off, 0 6 A pril 2 0 2 0. 
Of  t he 3 0 healt h y part ic i pa nts w h o recei ve d eit her L Y 3 4 9 3 2 6 9 or  2 6 ( 8 6. 7 %) re p orte d 
at l east 1 treat m e nt -e m er ge nt a d verse e ve nt ( T E A E). 
C o nsiste nt wit h t he i ncreti n class, GI e ve nts s uc h as a b d o mi nal diste nsi o n, na usea, v o mit i n g, a n d 
di arr hea were t he m ost c o m m o nl y  re p orte d A Es i n St u d y  G Z H A. I n a d dit i o n, decrease d a p peti t e 
was als o 1of  t he m ost f re q ue nt l y re p orte d A Es. All T E A Es were c o nsi dere d as mil d i n se verit y
b y t he i n vesti gat or , e ve n t h o u g h s o me re q uire d treat me nt . An i ncrease i n t he n u m ber of A Es 
rel ate d t o st u d y  dr u g was n ote d wit h i ncreasi n g d oses of L Y [ADDRESS_1258666] o ut of 6 prese nte d na usea, a n d n o ne 
prese nte d v o mit i n g. H o we ver, 3 s u bjects o ut of 6 i n C o h ort 3 recei vi n g   re p orte d GI A Es 
of  na usea a n d v o mit i n g, re q ui ri n g a nt i- e m et ic s. Se veral ot h er GI A Es were re p orte d i n C o h ort 3 
(f o r e xa m ple, a b d o mi nal pai n u p per, c o nsti pat i o n, er uctati o n, e pi [INVESTIGATOR_897965] o mf o rt, dr y  m o ut h, 
a n d d ys pe ps ia. )n ot pre vi o usl y re p orte d i n t he ot her c o h orts. 
No cli nicall y  si g nifica nt c ha n ges i n la b orat or y  d at a , n o i njecti o n -si te reacti o ns, or se vere 
h y p o gl yce mia e ve nts were n ote d. 
A d ose - de pe n de nt i ncrease i n heart rate ( H R) was n ote d, w hic h is c o nsiste nt wit h t he i ncret i n 
cl ass ( L ore nz et al .2 0 1 7). W hile n o cli nicall y  si g nifica nt c ha n ges were n ote d i n 
el ectr ocar di o gr a m  ( E C G ) res ult s, 3 parti ci pa nts i n  prese nte d mil d A Es of 
tac h y c ar di a. N o si g nifica nt c ha n ges i n t he bl o o d press ure meas ure me nts were n ote d . T he 
ma xi m u m H R (s u pi [INVESTIGATOR_050]) f or all [ADDRESS_1258667] d ose ; t he H R f o r t he se [ADDRESS_1258668] d ose. 
Si xparti ci pa nts recei ve d t he i nt ra ve n o us d ose as pla n ne d . Mil d e ve nts of decrease d 
a p peti te a n d GI e ve nts s uc h as a b d o mi nal diste nsi o n a n d na usea we re n ote d .C CI 
C CI 
C CI 
C CI 
C CI 
C CI C CI 
C O N FI D E N TI A L Pr ot oc ol  J 1 X -M C -G Z H C ( c) 
[ADDRESS_1258669] u g 
c o nce ntrati o n (t ma x ) was  cl ose t o pr o p orti o nal i ncrease i n e x p os ures wit h i ncreasi n g 
d ose a n d a half -life of  , w hic h is s ui t a bl e f or a wee kl y  d osi n g i nt er val .
Preli mi nar y P D data s u g gest L Y [ADDRESS_1258670] ( O G T T) .
F urt her details are a vaila ble i n t he I n vest i gat or’s Br oc h ure (I B) f or L Y 3 4 9 3 2 6 9. 
2. 3. Be nefit/ Ris k Assess me nt 
T here i s n o a ntici pate d t hera pe uti c be nefi t f or t he parti ci pa nts i n t hi s tri al. 
T he s p o ns or has e val uate d t he precli nical a n d cli nical ri s ks ass oci at e d wi t h  L Y [ADDRESS_1258671] u di es i n rats a n d m o n ke ys. I m p orta nt L Y 3 4 9 3 2 6 9- relate d 
fi n di n gs i n t he rat a n d m o n ke y i ncl u de d b o d y  wei g ht l os s a n d/ or re d uce d b o d y  w ei g ht gai n a n d 
decrease d f o o d c o ns u m pt i o n. A d dit i o nal fi n di n gs fr o m t he m o n ke y  st u dies, i ncl u di n g c ha n ges i n 
C V para m eters (s uc h as i ncreases i n H R a n d bl o o d press ure). I n St u d y  G Z H A, si milar fi n di n gs 
were o bser ve d, w hic h i ncl u de 
na usea 
v o mit i n g 
l o ss o fa p pet it e, a n d 
i ncrease d H R. 
Refer t o t he I B f or m ore i nf or mat i o n a b o ut t he n o ncli nical a n d cli nical data of L Y [ADDRESS_1258672] a y f o r f urt her safet y m o nit ori n g. 
Refer t o t he I B f or m ore i nf or mat i o n a b o ut t he n o ncli nical a n d cli nical data of L Y 3 4 9 3 2 6 9. M ore 
detaile d i nf or mat i o n a b o ut t he k n o w n a n d e x pecte d be nefit s a n d ris ks a n d reas o na bl y e x pecte d 
A E s of L Y 3 4 9 3 2 6 9 ma y  b e f o u n d i n t h e I B. 
Refer t o t h e Prescri bi n g I nf or mati o n f or Tr ulicit y ( Tr ulici t y  U ni te d States Pac ka ge I nsert, 2 0 1 9) 
f o r m or e i nf or mat i o n a b o ut t he k n o w n a n d e x pecte d be nefit s a n d ris ks o f d ul a gl ut i de .C CI 
C CI 
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
203. Objectives and Endpoints
Objectives Endpoints
Primary
To investigate the safety and 
tolerability of LY3493269 
following 4 once -weekly SC dosesTEAEs and SAEs
Secondary
To characterize the PK of 
LY3493269 following 4 once -
weekly SC dosesCmaxand AUC
To evaluate the change in FG 
following 4 once -weekly SC doses 
of LY3493269 and dulaglutideChange f rom baseline in FG
Explo ratory
To explore PD effects of 
LY3493269 and dulaglutide 
following 4 once -weekly SC dosesChange f rom baseline in mean daily PG (6-point PG profile)
Change f rom baseline in HbA1c
Change f rom premeal fasting during OGTT for
oPG concentrations
oinsulin concentrations
oC-peptide concentrations
oglucagon concentrations
Change f rom baseline in indices o f beta -cell function
HOMA2 -B
disposition index from OGTT
ΔI30/ΔG30 from OGTT
Insulin AUC 0-120min from OGTT
Change f rom baseline in
ofasting insulin sensitivity indices
HOMA2 -IR
fasting insulin
opostprandial insulin sensitivity indices
Matsuda
OGIS
Stumvoll
Change f rom baseline in fasting lipid parameters
triglycerides
total cholesterol, and
LDL -, HDL -, and VLDL -cholesterol, and
Change f rom baseline in body weight
Change f rom baseline in waist circumference
Change f rom baseline in g astric emptying
Change in appetite visual analog scale at fasting
To characterize the 
immunogenicity of LY3493269 
following 4 once -weekly SC dosesIncidence of treatment -emergent ADA
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
21Abbreviations: ADA = antidrug antibody; AUC = area under the concentration versus time curve; AUC 0-120min = 
AUC from 0 to 120 minutes; Cmax= maximum observed drug concentration; ΔG30 = 30-minute glucose in 
OGTT -baseline (0 minute) fasting glucose in OGTT ; ΔI30 = 30-minute insulin in OGTT -baseline (0 minute) 
fasting insulin in OGTT ; FG = fasting glucose; HbA1c = glycated hemoglobin; HDL = high -
density lipoprot ein; 
HOMA 2-IR = homeostatic model assessment for insulin resistance; HOMA2 - B = updated homeostatic model 
assessment for beta -cell function; LDL = low -density  lipoprotein; OGIS = oral glucose insulin sensitivity; OGTT 
= oral glucose tolerance test; PD = pha rmacody namics; PG = plasma glucose; PK = pharmacokinetics; SAE = 
serious adverse event; SC = subcutaneous; TEAE = treatment -emergent adverse event; VLDL = very low -density  
lipoprotein.
C O N FI D E N TI A L Pr ot oc ol  J 1 X -M C -G Z H C ( c) 
[ADDRESS_1258673] u d y  i n pat ie nt s wi t h  T 2 D M. 
Tr ulicit y ( d ula gl ut i de) will be use d as a p osit i ve c o ntr ol f or P D of G L P -[ADDRESS_1258674] u d y  i nt er ve nt i o n f o r 4 wee ks 
(Fi g ure 1). T he i n vesti gat or or desi g nee will a d mi nister t he st u d y i nter ve nt i o n at t he i n vesti gate 
si t e. 
P arti ci pa nts f o u n d t o be eli gi ble acc or di n g t o t he st u d y  e ntr y  cri t eri a will  b e ra n d o ml y assi g ne d 
t o recei ve L Y [ADDRESS_1258675] b o Q W f o r 4 wee ks. De pe n di n g 
o n t heir c o h ort, partici pa nts ra n d o ml y  assi g n e d t o L Y 3 4 9 3 2 6 9 will recei ve  
Q W f o r 4 wee ks ( Ta ble 2). C o h orts 1 a n d 2 will recei ve 4 fi xe d d oses. C o h orts 3 a n d 4 will 
recei ve t he wee kl y  d oses i n ste p wi se i ncre me nts , as g ui de d b y  e mer gi n g t ol era bili t y , P K, a n d/ or 
P D data i n t h e prece di n g d ose c o h orts. 
T he nee d t o a dj ust t he starti n g d ose of a c o h ort ( C o h orts 2, 3 ,a n d 4) a n d d ose -escalat i o n 
decisi o ns wi t hi n C o h orts [ADDRESS_1258676] i gat or a n d s p o ns or after re vie w of all a vaila ble data ( Secti o n 6. 6 ). 
Eac h partici pa nt’s i n v o l ve me nt i n t he st u d y  i s e x pecte d t o last u p t o 1 6 wee ks, i ncl u di n g a 
6- wee k scree ni n g peri o d 
1-wee k baseli ne peri o d 
4-wee k treat me nt peri o d, a n d 
A mi ni m u m [ADDRESS_1258677] i gat or ’s C CI C CI 
C CI 
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
23medical judgment. If required, the inpatient period may be extended to facilitate adherence to site 
policy , local gui delines ,and/orregulat ions. 
4.1.1. Screening Period
The outpatien t screening visit may be up to 42 days prior to enrollment. Individuals who are not 
enrolled within 42 days of screening shall undergo an addit ional medical assessment and/or 
clinical measurements (including but not limited to clinical laboratory  tests, ECG, vi tal signs, 
weight,and waist circumference measurements) to confirm their eligibilit y. Parameters that m ay 
be repeated for screening include clinical laboratory tests, ECGs, and vital signs.
4.1.2. Baseline Period
During this baseline period, participants may be admitted to the investigative site on Day  -[ADDRESS_1258678] igative site. 
Participants shoul d com plete the study  assessments and procedures planned during this period as 
specified in Section 1.3.
Eligible participants will be rando mly assigned to study  interventi on on the m orning o f Day 1:
8 to LY3493269
2to placebo, and
2 to dul aglut ide.
If eligible per screening window and inclusio n/exclusio n criteria, participants who com plete the 
baseline assessments but are not assigned to study  intervent ion on the fo llowing day  may repeat 
the baseline assessments once, on a later occasion, if it falls within the screening window of [ADDRESS_1258679] review the 
diaries at each return visit to the s ite.
C O N FI D E N TI A L Pr ot oc ol  J 1 X -M C -G Z H C ( c) 
[ADDRESS_1258680] i gat i ve site o n Da ys 2 4 a n d 3 0. P artici pa nts ma y 
r e m ai n resi de nt at t he si te o n Da y s 2 5 a n d 2 6 per i n vesti gat or’s discret i o n, t o facilitate site 
l o gist ic sa n d/ or c o m plia nce t o t he sc he d ule d assess me nts o n t hese da ys .
T hree o ut pati e nt visi tsare pl a n ne d o n Da y s [ADDRESS_1258681] u g a nt i b o d y  ( T E -A D A )
p osi ti ve at t he fi nal visit, he or s he s h o ul d u n der g o a d dit i o nal m o nit ori n g as descri be d i n Sect i o n
9. 4. [ADDRESS_1258682] u g ( Secti o n 7. 2 ). 
4. 2. Scie ntific R ati o n ale f or St u d y Desi g n 
Se q ue nti al st u d y desi g n 
T his st u d y  will  be t he first assess me nt of t he safet y a n d t ole ra bili t y  of  m ul ti ple d oses of 
L Y [ADDRESS_1258683] u g a nt i b o dies ( A D As )o n i nter pretati o n of cli nical data. 
Ste p wise d ose esc al ati o n wit hi n c o h ort 
T he S A D St u d y  G Z H A de m o nstrate d t hat d ose l e vels of  were ass ociate d wit h GI 
A Es. Gastr oi ntest i nal e ve nts (i ncl u di n g na usea a n d v o mit i n g) were ge nerall y  d ose de pe n de nt. 
Ste p wi s e d ose i ncreases ma y pr o ve usef ul as a p ote nt ia l mit i gat i o n f o r t hese GI effects. T his 
a p pr oac h f or escalati n g d oses f or a dr u g wit h G L P -[ADDRESS_1258684] c o m paris o n of safet y , t ol era bilit y, a n d P D data. C CI 
C CI 
C O N FI D E N TI A L Pr ot oc ol  J 1 X -M C -G Z H C ( c) 
[ADDRESS_1258685] i n i de nt if yi n g a n a p pr o priate d ose ra n ge f or 
t h e ne xt c o h ort i n t his st u d y , a n d 
s u bse q ue nt cli nical st u dies. 
S af et y a n d t ol era bilit y assess me nts will be ma de o ver all d ose le vels, i ncl u di n g i nci de nce o f 
na usea a n d/ or v o mit i n g, a n d e val uat i o n of vital si g ns a n d E C Gs. See Secti o n 6. 6 f o r decisi o ns o n 
d oses. 
4. 2. 1. P artici p a nt I n p ut i nt o Desi g n 
T hr o u g h o ut t his pr ot oc ol, t he ter m “partici pa nt ”is use d t o i n dicate a n i n di vi d ual w h o partici pates 
i n a cli nical trial, as a reci pie nt of a st u d y  i nt er ve nti o n. T his usa ge reflects prefere nces i n dicate d 
b y patie nt a d v ocates t o m ore acc uratel y  reflect t he r ol e of  pe o ple w h o ta ke part i n cli nical trials. 
4. 3. J u stific ati o n f or D ose 
St u d y  G Z H C pla ns t o e val uate a d ose ra n ge of   of L Y [ADDRESS_1258686] i o n usi n g a Q W d ose re gi me n w hile pr o vi di n g earl y i nf or mat i o n o n p ote ntial gl yce mic 
efficac y . 
 
 T his d ose ra n ge was selecte d f o ll o wi n g 
e val uat i o n of n o ncli nical data a n d res ults (t olera bilit y,  safet y,  P K, a n d P D) fr o m t h e S A D st u d y , 
G Z H A. St u d y  G Z H A e val uate d L Y [ADDRESS_1258687] le vel ( N O A E L )a n d m o n ke y 
NO A E L t o t his starti n g d ose are 0. [ADDRESS_1258688] u d y  b y ut ilizi n g 
a ste p wise d ose -escalat i o n a p pr oa c h ( C os k u n et al. 2 0 1 8; Frias et al. 2 0 1 8). I n t h ose st u dies, 
hi g her d ose le vels were better t olerate d usi n g a ste p wise d ose -escalati o n sc he me of 
a d mi nistrati o n a n d were a ble t o i ncrease e x p os ure c o m pare d t o a S A D st u d y .S af et y data fr o m 
St u d y  G Z H A s u p p ort t hi s a p pr oac h. 
Wit h se vere wei g ht l oss bei n g t he d ose -li mit i n g fact or i n a ni mals, t he mar gi n of safet yis less 
t h a n [ADDRESS_1258689] u di es, p ote nti al  ris ks f or C CI 
C CI 
C CI C CI 
C CI C CI C CI 
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
26clinical trial participants receiving LY3493269 include HR increase, body  weight l oss, GI 
effects, and appetite loss . All these ident ified risks are monitorable, manageable, and reversible.
The m argin o f safet y for the proposed MAD is presented inTable 3.
C O N FI D E N TI A L Pr ot oc ol  J 1 X -M C -G Z H C ( c) 
2 7 C CI 
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
284.4. End of Study Definition
A participant is considered to have co mpleted the study  if he or she has co mpleted all required 
visits of the study  including the last scheduled procedure shown in the Schedule of Act ivities
(SoA) .Any partici pant who does not satisfy this definit ion but who has completed all  the key  
assessments may be considered a completer at the discretion of the sponsor.
The end o f the study  is defined as the date of the last vis it of the l ast parti cipant in the study .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
295. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
Eligibilit y of parti cipants for the study  will be based on the results of screening medical history , 
physical examinat ion, vital signs, clinical laboratory tests ,and ECG. The nature of any 
condi tions present at the time of the physical examinat ion and any preexist ing condit ions will be 
docum ented.
Unless otherwise stated, the inclusio n and exclusio n criteria used to determine eligibilit y shoul d 
be applied at screening only, and not continuously throughout the trial.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply at 
screening :
Informed consent
1.Are capable of giving signed informed consent as described in Section 10.1.2 , whi ch 
include s com pliance wi th the requi rements and restrictions listed in the informed consent 
form (ICF) and in this protocol .
2.Are reliable and willing to make themselves available for the duration of the study  and 
are willing to fo llow study  procedures.
Participant characteristics
3.Are male or female not of childbearing potential from 18 to 70 years of age inclusive, at 
the time o f signing the informed consent.
Note: Contraceptive use by [CONTACT_134092]. For 
contraception requirements of this protocol, see Section 10.4.
4.Have a body  mass index of 23to 50 kg/m2, inclusive, at screening.
5.Have had a stable body  weight (<5% body weight change) for the [ADDRESS_1258690] 3months before screening .Patients wi th com orbid 
condi tions co mmo nly associ ated wi th diabetes ( for example, hypertensio n, 
hypercho lesterolemia, hypothy roidism) m ay be eligible for inclusio n if condit ions 
are assessed by [CONTACT_897977]
3months pri or to screening .
8.Have an HbA1c of at least 7.0% and no more than 10.5% at screening.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
309.Have clinical laboratory  test resul ts wi thin the normal range for the populat ion or 
investigat ive site, or with abnormalit ies deemed not clinically significan t by [CONTACT_1275].
10.Have venous access sufficient to allow blood sampling as per the protocol.
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply at screening :
Medical conditions
11.Have t ype [ADDRESS_1258691] ory of 
hypoglycemia unawareness or poor recognit ion of hypoglycemic symptoms .
Note: Any  parti cipant that cannot communicate an understanding of hypoglycemic 
symptoms and the appropriate treatment of hypoglycemia prior to the first dose of study  
drug should also be excluded.
15.Have a known clinically significant gastric empt ying abnormalit y (for example ,severe 
diabetic gastroparesis or gastric outlet obstruction), have undergone gastric by[CONTACT_6476] 
(bariatric) surgery  or restri ctive bariatric surgery (for example, Lap-Band®) or chroni cally  
take m edicat ions that direct ly affect GI m otilit y.
16.Have a definit ive diagnosis of autonomic neuropathy  as evidenced by  [CONTACT_221040], 
resting tachycardia, orth ostati c hypotensio n, or di abetic diarrhea .
17.Have obesit y induced by [CONTACT_597988], such as Cushing’s syndro me or 
Prader -Willi syndrome.
18.Have an estimated glomerular filtration rate less than 60 mL/min/1.[ADDRESS_1258692] 6 months prior to screening :
myocardial  infarct ion, 
unstable angina, 
coronary  artery  by[CONTACT_9292], 
percutaneous coronary  intervent ion (diagnostic angi ogram s are permitted), 
transi ent ischemic attack, 
cerebrovascular accident or decom pensated congestive heart failure, or 
[LOCATION_001] Health Associat ion Class III or IV heart failure.
20.Have an abnormalit y in the 12 -lead ECG at screening that, in the opi[INVESTIGATOR_3078] n of the 
investigator, increases the risks associated with participat ing in the study  or may 
confound QT data analysis, such as a QT interval corrected using Fridericia’s f ormula 
(QTcF )>450 msec for males and >470 msec for women, short PR interval (<120 msec) , 
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
31or PR interval >[ADDRESS_1258693] atrioventricular block, intraventricul ar 
conduction delay  with QRS >[ADDRESS_1258694] a mean supi[INVESTIGATOR_897966] 160 mmHg and a mean supi[INVESTIGATOR_897967] 95 mmHg from 2 assessments at screening
(excluding white -coat hy pertensio n); therefore, if a repeated measu rement shows values 
withinthe range, the patient can be included in the trial .
23.Have donated blood in the amount of [ADDRESS_1258695] known hemoglobinopathy (alpha 
thalassemia), hemo lytic anemia, sickle cell anemia, or have a hemoglo bin value less than 
11 g/dL in males or 10 g/dL in females, or any  othe r condit ion known to interfere with 
HbA1c methodology .
24.Have liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic 
hepat itis, or have elevat ions in aminotransferase level s (alanine aminotransferase [ALT ]
and aspartate aminotra nsferase [AST ]) greater than 3X upper limit of normal (ULN )at 
screening .
25.Have a history  of Gilbert’s syndrome or have total bilirubin level  (TBL )above 1.5X 
ULN at screening
.
26.Have a history  of acute or chronic pancreat itis.
27.Have a fasting serum triglycer ide level greater than 500 mg/dL at screening .
28.Have a history  of atopy  or clinically  significant m ultiple or severe drug allergies, 
intolerance to topi [INVESTIGATOR_90728], or severe posttreatm ent hy persensi tivity react ions 
(including, but not limited to, e rythema mul tiforme major, linear immunogl obulin A 
derm atosis, toxic epi[INVESTIGATOR_194], or exfo liative dermatit is).
29.Have a history  of or ongoing psychiatric disorders considered clinically significant in the 
opi[INVESTIGATOR_3078] n of the invest igator .
30.History  of drug o r alcoho l abuse .
31.Have a self or family history  (first -degree relat ive) of mult iple endocrine neoplasia t ype 
2A or ty pe 2B, thy roid C-cell hyperplasia, or medullary  thyroi d carcino ma.
32.Have calcitonin levels of 20 pg/mL or more at screening.
33.Have an act ive or untreated malignancy or have been in remission fro m a clinically 
significant malignancy  (other than basal or squamous cell skin cancer, in situ carcinomas 
of the cervix, or in situ prostate cancer) for [ADDRESS_1258696] ituting a risk while 
taking the study  medicat ion; or of interfering with the interpretation of data .
Prior/ concomitant therapy
35.Have taken any glucose -lowering medicat ions other than metformin, including insulin, in 
the past 3 months before screening.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
3236. Have been treated or plan to be treated with prescription medications that promote weight 
loss wi thin 3 m onths pri or to screening. Example s include
Saxenda®(liraglut ide 3.0 mg)
Xenical®(orlistat)
Meri dia®(sibutrami ne)
Acutrim®(phenylpropano lamine)
Sanorex®(mazindo l)
Adipex®(phentermine)
BELVIQ®(lorcaserin)
Qsymia™ (phentermine/topi[INVESTIGATOR_82336])
Contrave®(naltrexone/bupropi[INVESTIGATOR_2394]), or
other similar body  weight loss medicat ion including over-the
-counter ( OTC )
medicat ions (for example, allī®).
37.Have received chronic (last ing more than 14 consecutive days) systemic glucocorticoid 
therapy  (excluding topi [INVESTIGATOR_2855], intra -ocular, intra -articular, intranasal, or inhaled 
preparati ons) in the past y ear or have received any  glucocorti coid therapy wit hin 30 days 
before screening
.
38.Are current ly taking central  nervous system stimulant(s) (for example, Ritalin -SR®) with 
the except ion of caffeinated beverages, at screening .
39.Intend to use OTC or prescript ion medicat ion 4 weeks before planned dosing, apart from 
occasi onal intake of  vitamin/mineral  supplements and all owable concomi tant therapi [INVESTIGATOR_897968]6.5.
Prior /concurr ent clinical study experience
40.Have co mpleted or withdrawn from this study  or any  other study  invest igating 
LY3493269, and have previously received the study intervent ion.
41.Are current ly enrolled in a clinical trial invo lving a study  intervent ion or any  othe r type 
of medical research judged not to be scientifically or medically compat ible with this 
study .
42.Are current ly enrolled in or past participat ion, within the 30 days prior to screening, in a 
clinical study  involving a study  intervent ion for which at leas t 5 half -lives or 30 day s 
(whichever is longer) have not passed .
Diagnostic assessment s
43.Have posit ive findings on drug screening.
44.Show evidence of human immunodeficiency virus (HIV) and/or posit ive HIV ant ibodies 
at screening.
45.Show evidence of hepat itis B, positive hepat itis B core antibody, and/or posit ive hepat itis 
B surface ant igen.
46.Show evidence of hepat itis C and/or posit ive hepatit is C antibody .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
33Other exclusions
47.Have an average weekly alcoho l intake that exceeds 21 units per week (males) and 14 
units per week (females), or are unwilling to stop alcoho l consumpt ion from 24 hours 
prior to dosing day, unt il the pat ient has been discharged fro m the clinical research site (1 
unit = 12 oz. or 360 mL of beer; 5 oz. or 150 mL of wine; 1.[ADDRESS_1258697] illed 
spi[INVESTIGATOR_2120]).
48.Smoke m ore than 10 ci garettes, or cigarette equivalent (as determined by  [CONTACT_32839]), 
per day  or are unable to abide by  [CONTACT_897978] -
containing products .
49.Are females who are breast feeding.
50. Have kn own allergi es to LY3493269, GLP -[ADDRESS_1258698] 8 hours before
receiving study  intervent ion
each study  day when clinical safet y laboratory  and PD sam ples are collected, and
OGTTs are administered.
Water may  be consumed freely .
Standard meals will be administered in the invest igative site.
While outpati ent, parti cipants are encouraged to follow their usual dietary  regimen that is a part 
of their diabetes management, as agreed with the investigator or his/her designee.
5.3.2. Caffeine , Alcohol, and Tobacco
Caffeine
Parti cipants are allowed to maintain their regular caffeine consumpt ion throughout the study .
Alcohol
No al coho l is allowed
at least 24 hours before each weekly dosing ,
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
34at least 24 hours before each investigat ive site admissio n or outpatient visit, a nd
throughout the duration of each invest igative site visit.
A maximum of [ADDRESS_1258699] ioned about their nicotine consumpt ion habit s at scre ening.
Smoking, and the use of other tobacco or nicotine -containing products, will
be limited during the study  confinement according to invest igative site guidelines, and
not be permitted for [ADDRESS_1258700] ivity/exercise during 
the study .
Parti cipants will abstain from strenuous exercise wit hin 24 hours prior to admissio n to the 
investigat ive site.
When certain study  procedures are i n progress at the site, participants may  be requi red to rem ain 
recumbent or sitting.
5.4. Screen Failures
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequently enrolled in the study .
Individuals who do not meet the criteria for participation in this study (screen failure) may not be 
rescreened. However, participants who were eligible for inclusio n in previous cohorts, but were 
not random ly assigned for nonm edical reasons, may  be reassessed. Addit ional m edical 
assessments and clinical measurements must include clinical laboratory  tests, vi tal signs, and 
ECG to confirm their eligibilit y. Repeat of laboratory  tests will be acceptable if judged pertinent 
by [CONTACT_093] .
C O N FI D E N TI A L Pr ot oc ol  J 1 X -M C -G Z H C ( c) 
[ADDRESS_1258701] i gat i o nal i nt er ve nt i o n(s), m ar kete d pr o d uct(s), 
pl ace b o ,or m e dical de vice (s) i nt e n de d t o be a d mi nistere d t o / use d b y a st u d y  p arti ci pa nt 
acc or di n g t o t he st u d y  pr ot oc ol .
T he i n vest i gat or or desi g nee is res p o nsi ble f or 
e x plai ni n g t he c orrect use of t he st u d y  i nt er ve nt i o ns t o t he site pers o n nel ,
verif yi n g t hat i nstr ucti o ns are f o ll o we d pr o perl y ,
mai ntai ni n g acc urate rec or ds of st u d y  i nt er ve nti o n di s pe nsi n g a n d c ollect i o n, a n d 
ret ur ni n g all u n use d me dicati o ns t o t he s p o ns or or its desi g nee at t he e n d of t he st u d y .
N ote: I n s o me cases, sites ma y destr o y  t h e m at eri al if, d uri n g t he i n vest i gat i ve site select i o n, t he 
e val uat or has verifie d a n d d oc u me nte d t hat t he site has a p pr o priate facilit ies a n d wri tte n 
pr oce d ures t o dis p ose of t he cli nical materials 
6. 1. 1. A d mi nistr ati o n Det ails 
All i njecti o ns will be a d mi nistere d i nt o t he S C tiss ue of t he a b d o mi nal wall. I nject i o n sites will 
be alter nate d wee kl y  a m o n g 4 si tes (t hat i s, ri g ht a n d left u p per q ua dra nts a n d ri g ht a n d le ft  l o wer 
q ua dra nts) o n t he a b d o mi nal wall. W he ne ver p ossi ble, st u d y dr u g a d mi nistrati o n s h o ul d be 
carri e d o ut b y  t he sa m e pers o n nel. 
6. 2. Pre p ar ati o n/ H a n dli n g/ St or a ge/ Acc o u nt a bilit y 
Pre p ar ati o n 
I n vest i gat ors s h o ul d c o ns ult t he i nf or mat i o n pr o vi de d i n t he P har mac y  I nstr ucti o ns f or s pecific 
pre parati o n a n d a d mi nistrati o n i nf or mat i o n of L Y [ADDRESS_1258702] u d y i nter ve nt i o n C CI 
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
36must be prepared by  [CONTACT_897979] -related procedures.
Handling and storage
Only authorized site staff may supply or administer study  intervent ion. Study  interventi ons 
shoul d be stored in an environmentally  controlled and m onitored (m anual  or autom ated) area in 
accordance with the labeled storage c onditions wi th access limited to the invest igator and 
authori zed si te staff.
Accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ionsreceived and any  discre pancies are reported 
and reso lved before use of the study  intervent ion.
Only participants enro lled in the study  may receive study  intervent ion and only authorized site 
staff may supply or administer study  intervent ion. All study  intervent ion
smust be store d in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance 
with the l abeled storage conditions with access limited to the invest igator and authorized site 
staff.
The invest igator, institution, or the head of the medic al inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance ( that is,
recei pt, reconciliat ion, and final disposit ion records).
In some cases, sitesmay destroy  the m aterial if, during the i nvest igative site select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical materials. Otherwise, the investigator or designee will return all 
unused study  intervent ionsto the sponsor or designee at the end of the study.
Further gui dance and information for handling, storage, accoun tabilit y, and final disposit ion of 
unused study  intervent ions are provided in the Pharmacy Manual.
6.3. Measures to Minimize Bias: Randomization and Bl inding
Interactive web -response system
All participants will be centrally assigned to randomized study  intervent ion using an 
interact ive-web response system (IWRS)prior to or on Day  1. Bef ore the study  is init iated, the 
log in informat ion and direct ions for the IWRS will be provided to each site. Study  intervent ion 
will be dispensed at the study  visits summarized in the SoA. Returned study  intervent ionsshoul d 
not be re -dispensed to th e participants.
Blind break
The IWRS will be programmed with blind -breaking instructions. In case of an emergency , the 
investigator has the sole responsibilit y for determining if unblinding a parti cipants’ intervent ion 
assignment is warranted. Participant safet y must always be the first considerat ion in making such 
a determination. If a participant’s intervent ion assignment is unblinded, the sponsor must be 
notified immediately after breaking the blind. The date and reason that the blind was broken 
must be recorded in the source documentation and case report form (CRF) , as applicable.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
37Blinded study with unblinded site pharmacist who is dispensing drug
Parti cipants will be randomly assigned to receive study  intervent ion. Invest igators will remain 
blinded to each participant’s assigned study intervent ion throughout the course of the study . 
To maintain this blind, an otherwise uninvo lved third party (for exam ple, the pharmacist) will be 
responsible for the reconstitution and dispens ingof all study  intervent ion
sand will endeavor to 
ensure that there are no differences in t ime taken to dispense fo llowing rando mizat ion.In 
addition, the site personnel administering the study intervent ionswill not be blinded and will not 
perform  other protocol assessments to avo id bias. 
The dosing team may  blindfold the study  parti cipant to m aintain the blind at the time of dose 
administration . The participant will be instructed to avo id discussing the packaging of the study 
intervent ion with the investi gator.
In the event of a Qualit y Assurance audit, the auditor(s) will be allowed access to unblinded 
study  interventi on records at the si te(s) to verify that randomization/dispensing has been done 
accurately.
If an invest igator, site personnel performing assessments, or participan t is unblinded, the 
participant m ust be di scont inued fro m the study . In cases where there are ethical reasons to have 
the participant remain in the study , the investi gator m ust obtain specific approval from a sponsor 
clinical research physician ( CRP )for the participant to continue in the study.
6.4. Study Intervention Compliance
When the individual dose for a participant is prepared fro m a bulk supply, the preparation of the 
dose will be confirmed by a second member of the invest igativesite personnel .
When participants are dosed at the site, they  will receive study  intervent ion directly from  the 
investigator or designee, under medical supervisio n. The date and time of each dose administered 
in the clinic will be recorded in the source documents and recorded in the CRF. The dose of 
study  interventi on and study  parti cipant i dentificat ion will be confirmed at the time o f dosing by  
a member of the invest igativesite personnel other than the person administering the study  
intervent ion.
6.5. Concomitant Therapy
Recording of concomitant therapy
Any medicat ion or vaccine (including OTC or prescript ion medicines, vitamins, and/or herbal 
supplements or other specific categories o f interest) that the participant is receiving at the time of 
enrollment or receives durin g the study  must be recorded along with
reason for use
route of administration, and
dates of administration, including start and end dates.
Parti cipants will be instructed to consult the invest igator or other appropriate invest igativesite 
personnel before taking any  new medicat ions or suppl ements during the study . The sponsor’s 
medical mo nitor shoul d be contact[CONTACT_897980] .
C O N FI D E N TI A L Pr ot oc ol  J 1 X -M C -G Z H C ( c) 
[ADDRESS_1258703] u d y  u nless 
s pecificall y e xcl u de d i n t he pr ot oc ol ( Secti o n 5. 2 ). D oses m ust be sta ble as state d i n t he 
e xcl usi o n cri teria. Pa rti ci pa nts w h o ha ve bee n o n sta ble d oses of O T C or prescri pt i o n 
me dicat i o ns f or at least [ADDRESS_1258704] u d y . T hese m e dicati o ns ma y i ncl u de 
a nt i h y perte nsi ve a ge nts 
as pi [INVESTIGATOR_27969] n
li pi d -l o weri n g a ge nts, a n d 
met f o r mi n. 
P arti ci pa nts m ust be o n a st a ble d ose of metf or mi n f o r at  l east [ADDRESS_1258705] u d y .
Na usea a n d/ or v o mit i n g d uri n g t his s t u d y  m a y  b e treate d wi t h  a nt i- e met ics b ut t hese me dicati o ns 
s h o ul d n ot be use d pr o p h ylact icall y. 
Aceta mi n o p he n, at d oses of ≤ 2 g/ da y , i s per mitte d f or use a n y ti me d uri n g t he st u d y . H o we ver, 
aceta mi n o p he n s h o ul d n ot be all o we d after mi d ni g ht a n d u nt il t he last aceta mi n o p he n P K sa m ple 
is ta ke n f or t h e gastri c- e m pt yi n g test. 
Ot her c o nc o mita nt me dicat i o n ma y be c o nsi dere d o n a case - b y- case basis b y t he i n vest i gat or i n 
c o ns ultati o n wit h t he s p o ns or’ s m e dical m o ni t or, if re q ui re d. 
6. 6. D ose M o dific ati o n 
B y  n at ure of bei n g a d ose -escalat i o n st u d y , data will be e val uate d o n a n o n g oi n g basis u nt il t he 
ma xi m u m d ose is deter mi ne d or w he n st o p pi n g criteria are met. Safet y data, i n partic ular A Es, 
S A Es, a n d cli nicall y  i m p orta nt l a b orat or y  a b n or m ali ti es, are t he pri mar y  cri t e ri a f or d ose 
escalat i o n. I nteri m access t o st u d y  d at a i s sc he d ule d t o occ ur d uri n g t he st u d y  t o i nf or m  d ose -
escalat i o n decisi o ns, as s pecifie d i n Sect i o n6. 6. 1 .
T his pr ot oc ol all o ws s o me alterati o n fr o m t h e c urre nt l y o utli ne d d osi n g sc he d ule, b ut t he 
ma xi m u m d ose will n ot e xcee d  of L Y 3 4 9 3 2 6 9 . If c o nsi dere d a p pr o priate i n vie w of 
e m er gi n g safet y,  t ol era bilit y,  or P K data ,
act ual  d oses, i ncre me nts, a n d/ or d urati o n of d osi n g i n eac h c o h ort at eac h d ose le vel ma y 
be a dj uste d. 
the ti mi n g of t he sa m pli n g ma y be a dj uste d a n d a d dit i o nal l y t h e n u m ber of sa m ples t o be 
c ollecte d ma y be a dj uste d, as descri be d i n Secti o n 8. 5 .
the d urati o n of t he i n pat ie nt  sta y  or t he d urati o n of  s af et y f o ll o w- u p ma y  b e i ncrease d b ut 
n ot decrease d. 
N o d ose decisi o n ca n occ ur wit h o ut pri or disc ussi o n a n d a gree me nt bet wee n t he i n vest i gat or a n d 
s p o ns or. C ha n ges m ust be a p pr o priatel y d oc u me nte d a n d c o m m u nicate d b y  t he s p o ns or t o t he C CI 
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
39investigator. Because these adjust ments to timing or dose levels are allowable changes permitted 
by [CONTACT_760], they  woul d not requi rea protocol  amendment.
6.6.1. Dose Escalation
Dose Decisions between Cohorts
Preliminary safet y and tol erabili ty data from the current dose level, and any available data from 
preceding doses ,are the primary criteria for decisions jo intly made by [CONTACT_897981]
1) a dose escalat ion between successive cohorts, and
2) s tarting doses for Cohorts [ADDRESS_1258706] 5 participants who received 
LY3493269 through Day  15 at the preceding lower dose (Figure 1).
If available at the time of the dose -escalat ion decisio n, PK and PD results may be used as 
supporting data. Init iation of dosing for the last 2 planned cohorts will be based on review of the 
following:
1)All available PK data fro m Cohort 1, prior to init iation of  Cohort 3 
2)All available PK data fro m Cohor t 2, pri or to i nitiation of  Cohort 4.
Dose Decisions within Cohorts [ADDRESS_1258707] igator:
1.One treatm ent-emergent SAE believed to be associated with LY3493269 ; For more 
details see Section 7.1.2 .
2.One or m ore parti cipants on active drug experience 2 or more clinically  significant events 
(CSEs) deemed related to LY3493269. Clinically significant events are defined as 
moderate to severe AE, abnormal clinical signs , or clinical  laboratory  findings that may 
pose a risk to the well -being of the participant and would preclude further dosing of a 
participant who experiences this effect. C linically significant events will be determined 
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
40by [CONTACT_941] i nvestigator or suitable designee and may include findings that do not fulfill the 
criteria for SAEs .
3.Three or more participants at the same dose level experience any o f the following deemed 
related to LY3493269 administration: 
odrug-related GI effects (for example emesis, diarrhea) causing severe distress 
(prevents daily act ivities or requires an emergency  departm ent visi t or 
hospi [INVESTIGATOR_28689]); and/or 
oclinically significant cardiovascular AE .
4.40 % or m ore of parti cipants in a dose level experience a symptom atic hypoglycemic 
epi[INVESTIGATOR_897969] ≤2.8 mmo l/L (50 m g/dL; corresponding to plasma glucose (PG) 
levels o f ≤3.1 mmo l/L [56 m g/dL]) and these events are deemed to be related to 
LY3493269 administration (s ee Secti on7.1.2 ), or
5.Two or more participants on active drug develop persistent (>1 week) symptoms 
suggest ive of acute pancreat itis. Refer to algorithm for the monitoring of asymptomat ic 
hyperenzymemia in Sect ion10.7.
6.6.3. Data Review during the Study
Interim access to safet y, tolerabilit y, and any  available PK a nd PD data i s scheduled to occur 
after every  dosing sessio n. This schedule may  be modified as applicable, based on emerging 
safet y and tolerabilit y data. The purpose of these reviews is to guide and confirm dose selection 
for the next dosing cohort.
The de cision to proceed to the next cohort will be made by  [CONTACT_897982] y, tolerabili ty data (incl uding but not limited to AEs, concomitant medicat ions, 
clinical laboratory  tests, vi tal signs, ECG s) from at least [ADDRESS_1258708] timing of procedures and sampling schedules for th e current study .
6.7. Intervention after the End of the Study
Not applicable.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
417. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Section 10.1.7 .
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary  for a parti cipant to perm anent ly discont inue (definit ive 
discont inuat ion) study  intervent ion. If study  intervent ion is definit ively  discontinued, the 
participant will remain in the study  to be evaluated for early terminat ion safet y assessments and 
follow-up. See the SoA for data to be collected at the time o f discontin uation of  study  
intervent ion and fo llow-up and for any  further evaluati ons that need to be completed.
Parti cipants experiencing CSEs thought to be related to the study  intervent ion will be encouraged 
to com plete a 28 -day follow-up period before study discharge.
If a clinically significant finding is ident ified (including, but not limited to changes fro m baseline 
in QTcF) after enrollment, the invest igator or qualified designee will determine if the participant 
can cont inue in the study  and if any change in participant management is needed. This review of 
the ECG printed at the time of co llection must be docum ented. Any new clinically  relevant 
finding should be reported as an AE.
See the SoA for data to be collected at the time of intervent ion discontinuation and fo llow-up and 
for any  further evaluat ions that need to be completed.
7.1.1. Liver Enzymes and Other Laboratory
Discontinuati on of  the study  intervent ion for abnormal liver tests should be considered by [CONTACT_32845] a participant meets 1 of the fo llowing condit ions after consultation with the 
Lilly -designated m edical m onitor:
ALT or AST >8X ULN
ALT or AST >5X ULN sustained for more than 2 weeks or
ALT or AST >3X ULN and TBL >2X ULN or internat ional norm alized rati o (INR)>1.5 
or
ALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, right upper-
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
alkaline phosphatase ( ALP )>3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.[ADDRESS_1258709] with the appearance of fatigue, nausea, vo miting, right quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%).
Parti cipants who di scontinue from  study  intervent ion due to the abnormal liver tests will undergo 
monitoring as described in Sect ion10.6.
Discontinuati on of  the study  intervent ion due to abnormal laboratory  resul ts shoul d be 
considered by [CONTACT_82378] a patient meets 1 of the fo llowing condi tions after 
consultation wit h the sponsor- designated m edical  monitor:
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
42lipase and/or amylase ≥3X ULN (Section [IP_ADDRESS] should be considered by [CONTACT_1275]).
7.1.2. Persistent Hyperglycemia/Hypoglycemia
Discontinuati on of  the study  intervent ion shoul d be consi dered for parti cipants wi th any 
persistent severe hype rglycemia, defined as a persistent fast ing PGlevel above 240 mg/dL, 
without an i dentified cause (for example, intercurrent illness).
Discontinuati on of  the study  intervent ion shoul d be consi dered for parti cipants wi th any severe 
hypoglycemia (Level 3 acco rding to Section [IP_ADDRESS] ), or persistent hypoglycemic events (Level 
2),for example [ADDRESS_1258710] igator, after consultation with the sponsor -designated medical mo nitor, determines 
that a sy stemic hypersensit ivity reacti on has occurred related to study  drug administration, the 
participant shoul d be permanent ly discontinued from using the study  intervent ion.
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study
at any  time at his/her own request 
at the request of his/her designee (for example, parents or legal guardian)
atthe discretion of the invest igator for safet y, behavi oral, com pliance, or administrative 
reasons
if the participant beco mes pregnant during the study
if enro llment in any other clinical study invo lving an invest igational product or 
enrollment in any othe r type of  medical research judged not to be scient ifically or 
medically co mpat ible with this study , and
if the participant , for any  reason, requi res treatm ent wi th another therapeuti c agent that 
has been demonstrated to be effect ive for treatm ent of the st udy indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent .
Discontinuati on is expected to be uncommo n.
At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, as shown in the S oA.See SoA for data to be collected at the time of study  
discontinuat ion and fo llow-up and for any  further evaluat ions that need to be completed .The 
participant will be permanent ly discont inued both fro m the study  intervent ionand fro m the study  
at that time .
If the participant withdraws consent for disclos ure of  future inform ation, the s ponsor m ay retain 
and cont inue to use any data collected before such a withdrawal o f consent .If a participant
withdraws fro m the study , he/sh e may  request destructi on of  any sam ples taken and not tested ,
and the invest igator must document this in the site study records .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
437.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ify a participant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the participant shoul d be discont inued fro m study  treatm ent unless 
there are extenuating circumstances that make it medically necessary for the participant to 
continue on study  treatment.If the investigator and the sponsor CRP agree it is medically 
appropriate to continue, the invest igator must obtain documented approval fro m the sponsor CRP 
to allow the inadvertently enrolled participant to continue in the study  with or wi thout treatm ent 
with invest igational product. Safet y follow-up is as outlined in Sect ion 1.3(Schedule of 
Activities), Secti on 8.2(Safet y Assessments) , and Secti on 8.3(Adverse Events and Serious 
Adverse Events) of the protocol .
7.3. Lost to Follow -up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_17066].Site personnel are expected to 
make diligent attempts to contact [CONTACT_10971] a scheduled visit or were 
otherwi se unable to be fo llowed up by [CONTACT_779].
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
448. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA. Protocol waiver s or exem ptions 
related to eligibilit y criteria are not allowed.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon occurrence or 
awareness to determine if the participant should cont inue or discont inue study  intervent ion.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al participant s 
meet all eligibilit y criteria. The invest igator will maintain a screening log to record details o f all 
participant s screened and to confirm eligibilit y or record reasons for sc reening failure, as 
applicable.
Assessment collection time
The specificat ions in this protocol for the timings of safet y and sample co llection are given as 
targets to be achieved wit hin reasonable limits. Modificat ions may be made to the time po ints 
based upon emerging clinical informat ion. The scheduled t ime points may be subject to minor 
alterati ons; however, the act ual time must be correctly recorded in the CRF. Failure or being late 
(that is,outsi de st ipulated time allowances) to perform procedures or obtain samples wit hin the 
stipulated time allowances due to legit imate clinical issues (for example, equipment tech nical 
probl ems, venous access difficult y) will not be considered protocol deviat ions. However, the 
clinical research unit is required to notify the sponsor in writ ing using a file note.
8.1. Efficacy Assessments
Not applicable.
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA.
8.2.1. Physical Examinations
Com plete physical  examinat ions and symptom -directed phy sical examinat ions will be conducted 
at the visit s specified in Sect ion1.3. Symptom -directed phy sical examinat ions may also be 
conducted at other visits, as determined by [CONTACT_093], if a participant presents with 
complaints. A co mplete physical ex aminat ion will include, at a minimum, assessments of the
cardi ovascular
respi [INVESTIGATOR_696]
gastrointestinal, and
neuro logical systems.
Height and wei ght will  also be measured and recorded.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
458.2.2. Vital Signs
Vital signs, blood pressure, PR, and body  temperature, shoul d be m easured as specified in 
Secti on 1.3and as clinically indicated. Addit ional vital signs may  be measured during ea ch study  
period if warranted.
Blood pressure and PRshoul d be measured twi ce after at l east 5 minutes in a supi[INVESTIGATOR_23571].
Note: If white -coat hy pertensio n is suspected at screening, the participant can be included in the 
trial if a repeated measurement ( up to 2 additional assessments) shows values within the 
acceptable range.
If orthostatic measurements are required, participants should be supi[INVESTIGATOR_1919] [ADDRESS_1258711] igator, or qualified 
designee at the site as soon after the time of ECG col lection as possible. Ideally, the participant 
shoul d be present
to determine whether the participant meets entry  criteria at the rel evant visit(s), and
for immediate participant management, should any clinically relevant findings be 
ident ified.
The m achin e-read ECG intervals and HRmay be used for data analysis and report writing 
purposes unless a cardio logist overread of the ECGs is conducted prior to complet ion of the final 
study  report (in which case the overread data would be used).
Single electrocardiograms
Single ECGs will be collected at screening , baseline , at early  terminat ion, and fo llow-up on Day s 
36 and 57 according Section 1.3. Single ECGs may be obtained at addit ional times when deemed 
clinically necessary  to assess parti cipants’ safet y. All single ECGs recorded should be stored at 
the invest igational site. Single ECGs will not be transmitted to a central laboratory .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
46Triplicat e electrocardiograms
Triplicate [ADDRESS_1258712] be filed wit h the source documents. Clinically signifi cant abnormal 
laboratory  findings are those thatare not associated with the underlying disease, unless judged 
by [CONTACT_19448] ’s condi tion.
All laboratory  tests wi th values considered clinically  signi ficantly abnorm al during parti cipat ion 
in the study  or approximately  [ADDRESS_1258713] igator o r medical mo nitor.
If such values do not return to normal/baseline wit hin a peri od of  time judged reasonable 
by [CONTACT_093], the etio logy should be identified and the sponsor notified.
All protocol -requi red laboratory  assessments, as defined in Sect ion10.2, must be 
conducted in accordance with the laboratory  manual  and the SoA.
If laboratory  values fro m nonprotocol -specified laboratory  assessments performed at the 
institution’s l ocal laboratory  requi re a change in parti cipant m anagement or are 
considered clinically significant by  [CONTACT_17062] ( for example ,SAE or AE or dose 
modificati on), then the results must be recorded in the CRF.
8.2.5. S afety Monitoring
The sponsor clinical pharmaco logist or CRP/sci entist will  monitor saf ety data throughout the 
course of the study .
The sponsor will review SAEs within time frames mandated by  [CONTACT_631713]. The 
sponsor’s clinical pharmaco logist or CR P will periodically review
trends in safety  data
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
47laboratory  analy tes, and
AEs.
When appropriate, the sponsor’s clinical pharmacologist or CRP will consult with the 
funct ionally  independent Global Patient Safet y therapeuti c area physician or clinical resea rch 
scientist.
[IP_ADDRESS]. Hepatic Safety
Close hepatic monitoring
Laboratory  tests (Secti on10.6), including ALT, AST, ALP, TBL, direct bilirubin , gamma -
glutamyl transferase , and creatine kinase , shoul d be repeated wi thin 48 to 72 hours to confirm 
the abnormalit y and to determine if it is increasing or decreasing, if one or more of these 
condi tions occur:
If a participant with baseline results of... develops the following elevations:
ALT or AST <1.5x ULN ALT or AST ≥3x ULN
ALP <1.5x ULN ALP ≥2x ULN
TBL <1.5x ULN TBL ≥2x ULN (except for patients with Gilbert’s syndrome)
ALT or AST ≥1.5x ULN ALT or AST ≥2x baseline
ALP ≥1.5x ULN ALP ≥2x baseline
TBL ≥1.5x ULN TBL ≥2x baseline (except for patients with Gilbert’s syndrome)
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
TBL = total bilirubin; ULN = upper limit of normal.
If the abnormalit y persists or worsens, clinical and laboratory mo nitoring, and evaluat ion for 
possible causes of abnormal liver test resul ts should be init iated by  [CONTACT_32844] h the Lilly -designated m edical m onitor. At a minimum, thi s evaluat ion shoul d 
include physical examinat ion and a thorough medical history , including symptoms, recent 
illnesses (for example, heart failure, sy stemic infecti on, hypotensi on, or sei zures), recent travel, 
history  of concomi tant m edicat ions (including OTC ), herbal and dietary  supp lements, history  of 
alcoho l drinking and other substance abuse.
Initially, m onitoring of  symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the parti cipant’s clinical condit ion and hepat ic biochemical test s. 
Subsequently, the frequency  of monitoring m ay be l owered to once every  1 to 2 weeks, if the 
participant’s clinical condit ion and l aboratory results stabilize. Monitoring of ALT, AST, ALP, 
and TBL should continue unt il levels norm alize or return to appro ximate baseline levels.
Comprehensive hepatic evaluation
A co mprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
1or more of these condit ions occur:
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
48If a participant with baseline results 
of...develops the followi ng elevation:
ALT or AST <1.5x ULN ALT or AST ≥3x ULN with hepatic signs/symptomsa, orALT or AST ≥5x 
ULN
ALP <1.5x ULN ALP ≥3x ULN
TBL <1.5x ULN TBL ≥2x ULN (except for patients with Gilbert’s syndrome)
ALT or AST ≥1.5x ULN ALT or AST ≥2x baseline with hepatic signs/symptomsa, orALT or AST 
≥3x baseline
ALP ≥1.5x ULN ALP ≥2x baseline
TBL ≥1.5x ULN TBL ≥1.5x baseline (except for patients with Gilbert’s syndrome)
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST =aspartate aminotransferase; 
TBL = total bilirubin; ULN = upper limit of normal.
aHepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper -quadrant abdominal pain, fever, rash, 
and/o r eosinophilia >5%.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined earlier , as well as tests for prothro mbin t ime-INR; tests for viral hepatit is A, 
B, C, or E; tests for autoimmune hepatit is; and an abdo minal imaging study (for example, 
ultrasound o r computed tomography [ CT]scan).
Based on the patient’s history  and ini tial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tests for
hepat itis D virus
cytomegalovirus
Epstein -Barr virus
acetaminophen levels
acetaminophen protein adducts
urine toxico logy screen
Wilson’s disease
blood alcoho l 
levels
urinary  ethyl  glucuronide, and
serum  phosphat idylethano l.
Based on the circumstances and the invest igator’s assessment of the participant’s cli nical  
condi tion, the invest igator should consider referring the participant for a
hepatol ogist or gastroenterologist consultation
magnet ic resonance cho langiopancreatography
endoscopi c retrograde cholangiopancreatography
cardi ac echocardi ogram , or
liver bi opsy.
Additional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liver test result s during the study
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
49Addit ional hepatic safet y data collect ion in hepat ic safet y CRF sshoul d be performed in study  
participants who meet 1 or more of the fo llowing 5 condi tions:
1.Elevat ion of serum ALT to ≥5x ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5x ULN)
a.In parti cipants wi th baseline ALT ≥1.5x ULN, the thresho ld is ALT ≥3x baseline 
on 2 or more consecutive tests
2.Elevat ion ofTBL to ≥2x ULN (if baseline TBL <1.5x ULN) (except for cases of known 
Gilbert’s syndrome)
a.In parti cipants wi th baseline TBL ≥1.5x ULN, the thresho ld should be TBL ≥2x 
baseline
3.Elevat ion of serum ALP to ≥2x ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5x ULN)
a.In parti cipants wi th baseline ALP ≥1.5x ULN, the thresho ld is ALP ≥2x baseline 
on 2 or more consecutive blood tests
4.Hepati c event consi dered to be a nSAE
5.Discontinuati on of  study  drug due to a hepati c event
Note: the interval between the [ADDRESS_1258714] 2 day s.
[IP_ADDRESS]. Nausea, Vomiting, and Diarrhea
Nausea, vo miting, and diarrhea events are considered AEs of interest; each occurrence will be 
recorded as a discrete AE in the CRF. For each event assessment of severit y, durati on (actual  
date together with onset and end t imes) and invest igator’s opi[INVESTIGATOR_3078] n of relatedness to 
investigat ional product and protocol procedure will be captured.
[IP_ADDRESS]. Pancreatic Safety
Diagnosis of acute pancreatitis
Acute pan creat itis is an AE of interest in all studies with LY3493269, including this study. The 
diagnosis of acute pancreat itis requires 2 of the fo llowing 3 features (Banks and Freeman 2006 ; 
Koizumi et al. 2006 ):
abdo minal pain, characterist ic of acute pancreat itis (that i s, epi [CONTACT_24365] c pain radiat ing to the 
back, often associated with nausea and vo miting)
serum  amylase (total, pancreat ic, or both) and/or lipase ≥3X ULN
characterist ic findings of acute pancreat itis on CT scan or magnet ic resonance imaging 
(MRI ).
Ifacute pancreat itis is suspected, the invest igator should
obtain appropriate laboratory  tests, including p -amylase and lipase
perform  imaging studies, such as abdo minal CT scan wit h or without contrast, or 
abdo minal MRI
evaluate for possible causes of acut e pancreatit is, including alcoho l use, gallstone/gall 
bladder disease, hypertriglyceridemia, and conco mitant m edicati ons.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
50Discontinuation for acute pancreatitis
If acute pancreat itis is diagnosed, the participant must discont inue use o f the study  intervent ion.
[IP_ADDRESS]. Injection -Site Reactions
Symptom s of a l ocal inject ion-site reacti on may  include
erythema
induration
pain
pruri tus, and
edem a.
If an injection -site event i s reported, the AE will be recorded, and addit ional data will be 
provi ded to the sponsor in the electroni c case report form  (eCRF).
[IP_ADDRESS]. Hypersensitivity Reactions
Many  drugs, but parti cularly bio logic agents, carry the risk of systemic hypersensit ivity 
reacti ons. If such a reacti on occurs, addi tional data describing each symptom  shoul d be provi ded 
to the sponsor in the eCRF .
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  parti cipants are receiving study  drug. It is recommended that participants 
who experience a systemic hypersensit ivity react ion be treated per national and internat ional 
guidelines.
In case of anaphylaxis or generalized urticaria, addit ional blood sam ples shoul d be collected as 
described in Section 10.8. The lab oratory resul ts are provi ded to the sponsor vi a the central  
laboratory .
8.2.6. Glucose Monitoring
[IP_ADDRESS]. Hypoglycemia
Site personnel will collect informat ion on epi[INVESTIGATOR_897970]. Participants will be trained by  [CONTACT_897983], how to treat hy poglycemia, and how to collect appropriate informat ion for each 
epi[INVESTIGATOR_51943]. Site personnel will enter this informat ion into the eCRF a t each visi t.
Invest igators should use the fo llowing definit ions and criteria wh ile diagnosing and categorizing 
an epi[INVESTIGATOR_105397].
Note: The PG values in this sect ion refer to values determined by a laboratory  or Internati onal 
Federat ion of Clinical Chemistry  and Laboratory  Medicine plasma equivalent glucose meters 
and stri ps(ADA 2019) .
Glucose Alert Value (Level 1):
Documented symptomatic hypoglycemia is defined as any time a participant feels that 
he or she is experienci ng symptom s and/or si gns associ ated wi th hypoglycemia and has a 
PG level of ≤70 m g/dL (≤3.9 mmo l/L).
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
51Documented asymptomatic hypoglycemia is defined as any event not accompanied by 
[CONTACT_11017][INVESTIGATOR_82344] s of hypoglycemia, but with a measured PG ≤70 mg/dL (≤3.9 mm ol/L).
Documented unspecified hypoglycemia is define d as any  event wi th no inform ation 
about symptoms of hypoglycemia available, but with a measured PG ≤70 mg/dL 
(≤3.9 mmo l/L).
Clinically Significant Hypoglycemia (Level 2):
Documented symptomatic hypoglyce mia is defined as any time a participant feels that 
he or she is experiencing symptoms and/or signs associated with hypoglycemia and has a 
PG level of <54 m g/dL (<3.0 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not accompanied by 
[CONTACT_11017][INVESTIGATOR_82344] s of hypoglycemia, but with a measured PG <54 mg/dL (<3.0 mmo l/L).
Documented unspecified hypoglycemia is define d as any  event wi th no inform ation 
about symptoms of hypoglycemia available, but with a measured PG <54 mg/dL 
(<3.0mmo l/L).
Seve re hypoglycemia (Level 3):
Severe hypoglycemia is defined as an epi[INVESTIGATOR_105399], glucagon, 
or other resuscitative act ions. These epi[INVESTIGATOR_897971]. Blood glucose measurements may not be 
available during such an event, but neurological recovery  attributable to the restoration of 
BG to normal is considered sufficient evidence that the event was induced by a low BG 
concentration.
Other hypoglycemia categories:
Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between 
bedtime and waking.
If a hypoglycemic event meets the criteria of severe, the invest igator must record the event as 
serious on the AE CRF and report it to Lilly  as an SAE.
To avoi d duplicate reporting, all consecut ive PG values ≤70 m g/dL (3.9 mmo l/L) occurring 
within a 1- hour peri od m ay be considered to be a single hypoglycemic event (Weinberg et al. 
2010; Dan ne et al. 2013) .
In each case of suspected or confirmed hypoglycemia, it is important that the event be properly 
categori zed, the effect of the intervention be assessed, and the frequency of hypoglycemia be 
evaluated. The role o f dietary  changes and physi cal exercise (or any  other contribut ing factor) in 
the development of an event should be established by [CONTACT_093]. The participant should 
receive addit ional educat ion, if deemed appropriate. If applicable, please refer to the protocol 
section regard ing management of increased hypoglycemia risks.
[IP_ADDRESS]. Self-Monitoring of Blood Glucose
Prior to the first outpatient visit after the first SC dose, p articipants will receive training on 
routi ne BGmonitoring and paper diary  com pletion required during the study .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
52When outpatient, participants should measure their fast ing BGdaily  during the study .In 
addition, parti cipants shoul d test thei r glucose whene ver they  experience symptoms of 
hypoglycemia.
Parti cipants will be trained to record their results in their diaries. The investigator or designee 
must review the diaries at each return visit to the site.
8.3. Adverse Events and Serious Adverse Events
Adverse event swill be reported by  [CONTACT_17071] (or, when appropri ate, by  a caregiver, 
surrogate, or the participant's legally authorized representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording eve nts that m eet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study  procedures, or that 
caused the participant to discont inue the study  intervent ion orstudy  (see Secti on 7).
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All SAEs will be collected fro m the signing of the ICF until the parti cipation in study  has ended
.
All AEs will be co llected fro m the signing of the ICF until the follow-up visit.
Adverse events that begin before the start of study  intervent ion but after signing the ICF will be
recorded on the Adverse Event CRF.
Although all AEs after signing the ICF are recorded by [CONTACT_29558]/electronic data entry, 
SAE reporting to the sponsor begins after the patient has signed the ICF and has received study 
drug. However, if an SAE occurs after signing the ICF, but pri or to receiving study  intervent ion, 
it needs to be reported ONLY if it is considered reasonably  possibly  related to study  procedures.
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed [ADDRESS_1258715] igator learns of any SAE, including a death, at any t ime after 
a participan t has been discharged from the study , and he/she considers the event to be reasonably  
related to the study  intervent ion or study  parti cipati on, the invest igator must prompt ly notify  the 
sponsor .
8.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, eva luating, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Appendix 10.3.
Care will be taken not to introduce bias whil e detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about AE
occurrenc es.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
538.3.3. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/contacts. All SAEs and AEs of special interest (as defined in Sect ion 8.3.6 ),
will be fo llowed up until reso lution, stabilizat ion, the event is otherwise explained, or the 
participant is l ost to foll ow-up (as defined in Section 7.3).Further information on fo llow-up 
procedures is provi dedin Appendix 10.3.[ADDRESS_1258716] the safe ty of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion unde r clinical  investi gation. The 
sponsor will co mply wi th country -specific regulatory  requi rements relating to safet y reporti ng to 
the regulatory  authori ty, institutional review boards (IRB s)/independent ethics co mmittees
(IEC s), and invest igators.
An invest igator who receives an invest igator safety report describing a nSAE or other specific 
safet y informat ion (for example ,summary or list ing of SAEs) fro m the sponsor will review and 
then file it along with the IBand will notify the IRB/IEC, if appropr iate according to local 
requi rements.
8.3.5. Pregnancy
Pregnancy (maternal or paternal exposure to study  intervent ion) does not meet the definit ion of 
an AE. However, to fulfill regulatory  requi rements, any pregnancy  should be reported following 
the SAE process described in Section 10.4.[ADDRESS_1258717] data on the outcom e for both m other and 
fetus.
Details o f all pregnancies in female participants and female partners of male participants
will be co llected after the start of study  intervent ion and for the duration of the study  plus 
[ADDRESS_1258718] dose of study  
intervent ion.
If a pregnancy  is reported , the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy and should fo llow the procedures outlined in Appendix 10.4.
Abnorm al pregnancy outcom es (for example ,spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) are considered SAEs.
8.3.6. Adverse Events of Special Interest s
Adverse events of special interest for this program include
CV events
GI events
inject ion-site reacti ons
hypersensit ivity react ions, and
hypoglycemic events.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
54Each occurrence will be recorded as a separate AE in the CRF. For each event assessment of 
severit y, durati on (actual  date, time of onset, and end times), and investigator’s opi[INVESTIGATOR_3078] n of 
relatedness to study  interventi on and protocol  procedure will be captured.
8.3.7. Product Complaints
A product complaint is any written, electronic, or oral communicat ion that alleges deficiencies 
related to the identit y, qualit y, durabilit y, reliabilit y, safety, effect iveness ,or performance of a 
trial intervent ion.
The s ponsor collects product complaints on investigational products and drug delivery systems 
used in clinical studies to ensure the safet y of study  parti cipants, m onitor quali ty, and to facilitate 
process and product improvements.
Parti cipants will be instructed to contact [CONTACT_17074] a
complaint or probl em wi th the invest igational product so that the situation can be assessed.
NOTE: AE s/SAE sthat are associated with a product complaint will also fo llow the processes 
outlined in Sect ion 8.3.3 and Appendix 10.3.3 of the protocol .
[IP_ADDRESS]. Time Period for Detecting Product Complaints
Product complaints that resul t in an AEwill be detected, documented, and reported to the 
sponsor during all periods of the study in wh ich the drug/device is used.
If the inv estigator l earns of any product com plaint at any  time after a participant has been 
discharged from  the study , and such incident is considered reasonably related to a drug/ device 
provi ded for the study , the invest igator will pro mptly notify  the sponsor.
[IP_ADDRESS]. Prompt Reporting of Product Complaints to Sponsor
Product complaints will be reported to the sponsor within [ADDRESS_1258719] Complaint Form will be sent to the sponsor by  [CONTACT_897984] .If 
the primary method is unavailable, then an alternative method provided in the form shoul d be 
utilized.
[IP_ADDRESS]. Follow -up of Product Complaints
Follow-up applies to all participants, including those who discont inue study  intervent ion.
The invest igator is responsible for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the product comp laint.
New or updated informat ion will be recorded on the originally co mpleted form wit h all changes 
signed and dated by [CONTACT_32848] .
8.4. Treatment of Overdose
For thi s study , any dose of LY3493269 greater than the dose assign ed through randomizat ion 
will be considered an overdose. Treatment for overdose is supportive care. For addit ional details, 
refer to the LY3493269 IB.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
55In the event of an overdose, the invest igator or treating physician shoul d
1. c ontact the medical monitor immediately.
2. c losely monitor the parti cipant for any  AE/SAE and laboratory  abnorm alities unt il 
LY3493269 can no longer be detected sy stemically .
Decisio ns regarding dose interruptions or modifications will be made by [CONTACT_897985].
8.5. Pharmacokinetics
Plasma sam ples will be collected for measurement of plasma concentrations of LY3493269 as 
specified in Section 1.3.
A maximum of [ADDRESS_1258720] igator and the sponsor. The timing of sampling 
may be altered during the course of the study  based on newly available data ( for example ,to 
obtain data closer to the time of peak plasma concentrations) to ensure appropriate monitoring.
Instructi ons for the collect ion and handling of bio logical samples will be provided by t he 
sponsor. The actual date and time (24-hour clock time) of each sample will be recorded.
Samples will  be used to evaluate the PK of study  intervent ion. Sam ples co llected for analyses of 
study  interventi on plasma concentration may  also be used to evaluate safet y or efficacy aspects 
related to concerns arising during or after the study.
Genet ic analyses will not be performed on these plasma samples. Participant confident iality will 
be maintained.
Drug concentration informat ion that would unblind the study  will not be reported to invest igative 
sites or blinded personnel unt il the study has been unblinded.
8.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  [CONTACT_17077] a facilit y 
designated by  [CONTACT_456].
The retention period for bioanalyt ical samples co llected to measure LY3493269 concentrations 
is provided in Section 10.1.9 . Duri ng this time, samples remaining after the bioan alyses may  be 
used for exploratory  metabo lism studies or exploratory  analyses such as bioanaly tical assay 
validat ion or cross -validat ion exercises.
[IP_ADDRESS]. Bioanalysis of Study Intervention
Concentrations of LY3493269 will be assayed using a validated liquid chromatography  with 
tandem mass spectrometry method. Analyses of samples co llected fro m participants who 
received either placebo or dul aglut ide are not planned.
[IP_ADDRESS]. Bioanalysis of Acetaminophen
Concentrations of acetaminophen will be assayed using a validated liqui d chrom atography with 
tandem  mass spectrometry  method.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
568.6. Pharmacodynamics
8.6.1. Oral Glucose Tolerance Test
Glucose, C -pepti de, gl ucagon, and insulin will be measured in an OGTT to assess effects of 
LY3493269 on glycemic control, disposit ion index, insulin secret ion and insulin sensit ivity.The 
schedule for OGTTs is indicated in Section 1.3.
1.Parti cipants will maintain adequate carbohy drate intake (125 to150 g/day )[ADDRESS_1258721] and at 0.5, 1, 1.5 ,and 2 hours after th e init iation of the glucose 
load.
4.If participants develop symptoms of hypoglycemia, bedside BG concentration may  be 
measured. The participant will be treated per investigator
’sdiscreti on.
8.6.2. Gastric -Emptying Test
Acetaminophen is a well -established marker o f gastri c em ptying (Young 2005) . It is rapi[INVESTIGATOR_897972] m the stom ach. A delay in gastric empt ying is 
reflected in the alterations to the concentration versus time profile of acetaminophen, 
specifically, decreasing its maximum observed drug concentration (C max)andlikely delaying tmax
without al tering the extent (total drug amount) absorbed.
The acetaminophen dose should be given approximately [ADDRESS_1258722] igative site 
before each meal (breakfast, lunch, and dinner) and app roximately 2 hours after the end of each 
meal.
8.6.4. Pharmacodynamic Markers
Samples for PD m arkers will be collected at the times specified in Section 1.3.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
57Fasting serum samples for glucose, insulin, and C -pepti de will be evaluated as PD bio markers. 
Fasting lipi[INVESTIGATOR_805] (tri glyceri des, cholesterol , very low-densit y lipoproteins, low-densit y lipoproteins ,
and high -densit y lipoprotei ns) will be evaluated as explo ratory  mechanist ic markers.
Plasma and serum concentrations of these markers will be assayed using validated analy tical 
methods. Instructions for the collection and handling of samples for these analyses will be 
provi ded by [CONTACT_456].
8.6.5. Appetite Analysis with a Visual Analog Scale
To expl ore the effects of LY3493269 on meal intake and appet ite sensat ion, parti cipants will be 
asked to rate their appetite sensat ions using a 100- mm visual analog scale ( VAS )for param eters 
of hunger, fullness, sat iety, and prospective food consumpt ion prior to dosing and in the fasted 
state while inpat ient as well as on scheduled outpatient visits, according to Section 1.3.
The VAS is a validated tool to assess appetite sensation parameters (Flint et al. 2000). The VAS 
is presented as a 10 -cm (100 -mm) line, anchored by [CONTACT_61522], usually “extremely” and 
“not at all”. Participants are required to rate thei r subject ive sensat ions on four 100- mm scales 
combined wit h questions similar to the fo llowing:
1.“How hungry  do y ou feel?”
2.“How satisfied do y ou feel?”
3.“How full do y ou feel?”
4.“How m uch do y ou think y ou coul d eat?”
Invest igative site personnel will use a ca liper to measure the distance from [ADDRESS_1258723] the measurement in the source document. Overall 
appeti te score i s calculated as the average of the 4 individual scores: satiet y + fullness + (100 -
prospective food consumption) + (100- hunger) / 4 (van Can et al. 2014). The higher overall 
appeti te score indicates l ess appet ite, and the lower score indicates more appetite.
8.6.6. Body Weight
Weight will be measured as indicated in the SoA. Weight will be measured twice on each 
scheduled occasion, with the participant steppi[INVESTIGATOR_105404]. The m ean 
of the [ADDRESS_1258724] circumference will be measured twice on each scheduled occasion according to 
Secti on1.3. The m ean of  the 2 m easurements will be recorded in the source document and the 
eCRF.
Waist circumference should be measured at the midpoint between the lower margin o f 
the least palpable rib and the top of the iliac crest.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
58The patient should stand with feet close together, arms at the side and body  weight evenly  
distributed, and should wear little clothing.
The patient should be relaxed, and the measurements should be taken at the end of a 
norm al expi[INVESTIGATOR_57774].
8.7. Genetics
A blood sample for DNA i solation will be collected fro m participants. 
See Appendix 10.[ADDRESS_1258725] ion, variabilit y of parti cipant response (including safet y), and 
clinical outcome. Sample collection is incorporated into clinical studi es to enable examinat ion of 
these quest ions through measurement of bio molecul es including DNA, RNA, proteins, lipi[INVESTIGATOR_805], 
and other cellular elements.
Samples will  be used for exploratory  research on the drug target, disease process, variable 
response to LY3493269, pathways associated with T2DM, obesit y, or di abetes com plicati ons 
including nonalcoholic steatohepatit is (NASH ), mechanism  of action of LY3493269, and/or 
research method, or for validat ing diagnost ic tools or assay(s) related to T2DM, obesit y, or 
diabetes com plicati ons including NASH.
Exploratory  biomarker m easures may  include potent ial markers o f GIP and GLP -1Rtarget 
engagement and mechanism o f action.
Confidentiality
All samples will be coded with the participant number. These samples and any data generated 
can be linked back to the participant only by [CONTACT_41417] .
Sample retention
The purpose of retention, the maximum duration of retent ion, and facilit y for long-term storage 
of samples aredescribed in Sect ion10.1.[ADDRESS_1258726] LY3493269. Antibodies may  be further 
characterized for cross -reactive binding to native GIP and GLP -1. To interpret the results of 
immunogenicit y, a venous bl ood sam ple will  be collected at the same time points to determine 
the plasma concentrations of LY3493269.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
59TE-ADAs are defined in Sect ion9.4.[ADDRESS_1258727] scheduled assessment or discontinuation visit 
is TE -ADA positive, addit ional samples m ay be taken every  3 months unt il the ADA signal 
returns to baseline ( that is,no longer TE -ADA posit ive) or for up to [ADDRESS_1258728] igator’s discret ion. 
Parti cipants foll owed for at l east [ADDRESS_1258729] ion 10.1.9 .
8.10. Health Economic s
Not applicable.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
609. Statistical Considerations
9.1. Statistical Hypotheses
The primary  study  object ive is to determine the safety  and tol erabili ty LY3493269 fo llowing 4 
QW doses. Addit ional hypotheses will include the comparison of study  interventi on wi th placebo 
and/or dulaglut ide for the prespecified object ives and endpo ints defined in Sect ion3.
9.2. Sample Size Determination
Approximately  64 participants may be rando mly assigned to study  intervent ion such that 
approximately  
12 evaluable participants fro m each of the 4 cohorts complete the study . In each 
cohort, parti cipants will be rando mly assigned to
8 LY3493269
2 dulaglut ide, and
2placebo.
If participants are discontinued during the study , addi tional parti cipants m ay be enrolled as 
replacements for these participants .
The sample size is considered sufficient for eva luating the primary object ive of this study .
Participant replacement
A total o f 12participants are aimed to complete the study in each cohort.
Parti cipants who di scontinue from  the study , for reasons other than an AE suspected to be related 
to study  drug, may be repl aced as agreed between the sponsor and invest igator. The replacement 
participant will be assigned to the same treatment as the participant being replaced.
Parti cipants who di scontinue from  the tri al due to an AE considered by  [CONTACT_3170] t o be 
probably  or m ost likely  related to study  intervent ion will not be replaced.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
619.3. Populations for Analyses
The following popul ations are defined:
Population Definition
Entered All participants who sign the ICF.
Enrolled All participants randomly assigned to study intervention. 
Safety All participants randomly assigned to study intervention and who received at least [ADDRESS_1258730] evaluable 
PD sample.
Abbrevi ations: ICF = informed consent form; PD = pharmacodynamic s; PK = pharmacokinetic s.
9.4. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y of the sponsor or its designee. 
Statistical analyses will be conducted on the populations as described in Section 9.3. Safet y 
analyses will be conducted on the safet y popul ation whether or not they  com pleted all  protocol  
requi rements.
Any change to the data analysis methods described in the protocol will requ ire an amendment 
only if it changes a princi pal feature of the protocol. Any  other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the statist ical analysis plan (SAP)and the clinical study  report. Addi tional expl oratory  
analyses o f the data will be conducted as deemed appropriate.
The SAP will be finalized prior to thefirst patient visit and i t will include a m ore technical and 
detailed descri ption of  the statist ical analyses provided in this section.
9.4.1. General Considerations
Data list ings will be provided for all data that aredatabased. Data list ings will be provided for all 
participants up to the point of withdrawal, with any  parti cipants excl uded f rom the rel evant 
popul ationhighlighted.
Summary  statistics and stati stical analysis will only be presented for data where detailed in the 
SAP. Summary statist ics and statist ical analyses will generally only be performed for 
participants included in the relevant analysis population. For the calculat ion of summary  
statist ics and statist ical analysis, unrounded data will be used ( Table 4).
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
62Table 4. Data Presentation Methods
Parameters Summary Statistics
 demography
 clinical laboratory
 vital signs
 ECG
 appetite analysis, and
 PD data arithmetic mean
 arithmetic standard deviation
 median
 minimum
 maximum, and
 the number of observations
 PK data
o AUC (0-τ), and
o Cmax geometric mean and
 CV%
 adverse event data
 hypoglycemic classification data, and
 injection -site reaction data frequency count and
 percentages
Abbreviations: AUC (0-τ)= area under the concentration versus time curve during 1 dosing interval ; Cmax= 
maximum observed drug concentration; CV% = geometric coefficient of variation; ECG = electrocardiogram; 
PD = pharmacodynamic s; PK = pharmacokinetic s.
Mean change fro m baseline is the mean of all individual participants’ change fro m baseline 
values. Each individual change fro m baseline will be calculated by  [CONTACT_897986]’s baseline value fro m the value at the time point. Baseline is defined to be Day  1 
predose m easurements unless otherwise stated.
Data analysis will be performed using SAS®Version 9.[ADDRESS_1258731] ics. In addi tion, all 
clinical chemistry , hematol ogy, and urinalysis data outside the reference ranges will be tabulated 
by [CONTACT_58280].
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
63Analysis for vital signs
Vital signs will  be summarize d regarding observed values and change from baseline values by  
[CONTACT_897987]. For change fro m baseline values, a 
mixed model for repeated measurement with treatment, visit of measurement, and treatment -by-
visit i nteracti on as fixed effects, participant as random effect, and baseline as covariate will be 
used to determine the effects of LY3493269. Least squares means as well as 90% confidence 
intervals ( CIs) will be reported.
Analysis for electrocardiograms
Electro cardiogram parameters will be summarized, including the PR, QT, RR, and QTcF 
intervals, QRS durati on, and HR. A concentration -response analysis will also be performed to 
assess the effect of LY3493269 on QTcF. Addit ional analyses may  be perform ed to determ ine 
the effects of PK and PD parameters on QTcF and other intervals.
9.4.3. Pharmacokinetic Analyses
Pharmacokinet ic parameter estimates for LY3493269 will be calculated using standard 
nonco mpart mental methods of analysis. The primary  param eters f or analysis will be C maxand 
area under the concentration versus time curve ( AUC )of LY3493269 after the first and last dose .
Other parameters, such as tmax, half-life, apparent clearance, apparent volume of distribut ion,and 
accumulat ion rati o, may be reported. If deemed necessary, addit ional populati on PK m odeling
may be performed or data may be combined wit h other studies for further analysis.
Pharmacokinet ic dose proporti onali ty will be explored for the first dose of each cohort. Log -
transformed C maxand AUC o f LY3493269 will be evaluated using a power model, where log
dose acts as an explanatory  variable, to estimate ratios of dose -norm alized geo metric means and
corresponding 90% CIs. The estimated ratio of dose -normalized geometric means of PK 
param eters between the highest and lowest doses will be used to assess dose proportionalit y. A 
subinterval wit hin the highest and lowest doses may also be considered fo r assessment of dose 
proporti onali ty using the same approach. Addit ional details will be provided in the SAP.
The parameter t maxof LY3493269 will be analyzed using a nonparametric method. All PK 
param eters will  be summarized using descript ive statist ics.
9.4.4. Pharmacodynamic Analyses
All PD parameters, including the change from baseline parameters, will be summarized and 
tabul ated by  [CONTACT_266476]. Summary  statistics will be provided. The individual 
observed and mean time profile of the postdose PD param eters will be plotted by  [CONTACT_103466].
Pharmacodynamic parameters may be transformed before statist ical analyses, if deemed 
necessary . Absol ute val ues, as well as change from baseline, in each parameter will be analyzed 
using mixed model for repeat ed measurement to evaluate treatment effects, as well as treatment 
comparisons. The m odel will include treatment, visit, and treatment-by- visit interaction as fixed 
effects and participant as a random effect. Baseline values, as well as other influencing v ariables, 
may be used as covariates.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
64Inferences will be sought regarding the effect of LY3493269 on the PD endpoints. Such effects 
will be explored over different doses of LY3493269 and at applicable time po ints as per 
Secti on1.3.
Differences between each LY3493269 -treated group and dulaglut ide group will be est imated. 
Parti cipants who received dulaglut idewill be pooled across all cohorts.
Differe nces between each LY3493269 -treated group and placebo group will be est imated. 
Parti cipants who received placebo will be pooled across all cohorts. Least -squares means and 
90% CIs will be reported.
Acetaminophen parameters will be calculated using standard noncompartmental methods of 
analysis. The primary  parameters for analysis will be C max, AUC, and t maxof acetaminophen. 
Other PK parameters of acetaminophen may be reported where appropriate. Baseline -adjusted 
Cmaxof acetaminophen (ratio to Day  -1 value) will be calculated and logtransformed to compare 
the gastri c-emptying effect of LY3493269 to that of dulaglut ideand pl acebo . Amixed model for 
repeated m easurem entwith treatm ent, day , and treatm ent-by-day interact ion as fixed effects, 
participant as ra ndom effect, and baseline (Day -1) as covari ate will be used to perform the 
analysis. Least -squares means as well as 95% CIs will be reported. The parameter t maxof 
acetaminophen will be analyzed using a nonparametric method.
9.4.5. Pharmacokinetic/Pharmacodynamic Analyses
Pharmacokinet ic/PD analyses or graphical explorations may  be used to assess the relationship 
between LY3493269 doses and/or concentrations and key
safet y parameters, such as 
oQTcFinterval
oblood pressure
oHR, and
oPRinterval ,
tolerabilit y parameters, such as 
onausea and
ovomiting, and
PD parameters, such as 
ofasting glucose
oHbA1c, and
oweight.
Endpoints may include but are not necessarily limited to those listed earlier.
9.4.6. Evaluation of Immunogenicity
Upon full assay  validat ion, TE -ADAs may be assessed. The frequency and percentage of 
participants wi th preexist ing ADA and with TE -ADA+ to LY3493269 may be tabulated. 
Treatment -emergent ADAs are defined as those with a signal increase, greater than assay 
variabili ty, com pared to baseline. Treatment -emergent ADAs are defined as those with
a titer 2-fold (1 dilut ion) greater than the minimum required dilut ion if no ADAs were 
detected at baseline (treatment -induced ADA), or
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
65a 4-fold (2 dilut ions) increase in t iter compared to baseline if ADAs were detected at 
baseline (treatment -boosted ADA).
The frequency of cross- reactive binding to native GIP, GLP -1,or neutralizing ant ibodies may 
also be tabulated in TE -ADA+ participants, when available.
The rel ationship be tween the presence of ant ibodies and PK exposures and PD response 
including safet y and efficacy  to LY3493269 may be assessed.
9.5. Interim Analyses 
Interim access to safet y and tol erabilit y (and any available PK or PD) data is scheduled to occur 
after every  dosing sessio n as described in Sect ion 6.6.[ADDRESS_1258732] be amended.
Unblinding details are specified in the unblinding plan section of the SAP or in a s eparate 
unblinding plan document .
9.6. Data Monitoring Committee (DMC)
Not applicable.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
6610. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
consensus ethical principles derived fro m internat ional guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences
International Ethical Guidelines
applicable Internati onal Council for Harmonisat ion (ICH) good clinical practice (GCP)
Guidelines
applicable laws and regulations
The protocol, protocol amendments, ICF, IB, and other relevant documents ( for example ,
advert isements) must be submitted to an IRB/IEC by [CONTACT_250478]/IEC before the study is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to study  parti cipants.
The invest igator will be responsible for the fo llowing:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordanc e with the requi rements, policies, and procedures established by  
[CONTACT_1201]/IEC
Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required by 
[CONTACT_1744]/IEC procedures
Provi ding oversight of the conduct of the study  at the site and adherence to r equirements 
of 21 Code of Federal Regulat ions (CFR ), ICH guidelines, the IRB/IEC, European 
Regulati on 536/2014 for clinical studies (if applicable), and all other applicable local 
regul ations
Invest igator sites are compensated for participat ion in the studyas detailed in the Clinical 
Trial Agreement .
10.1.2. Informed Consent Process
The invest igator or his/her representative will explain the nature of the study , including the risks 
and benefits, to the parti cipant and answer all questi ons regarding the study .
Participants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants will be required to 
sign a statem ent of  inform ed consent that meets the requirements of 21 CFR 50, local 
regul ations, ICH guidelines, Health Insurance Portabilit y and Accountabilit y Actrequirements, 
where applicable, and the I RB/IEC or study  center.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
67The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained before 
the participant was enter ed in the study  and the date the written consent was obtained. T he 
authori zed person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant and is kept on file .
10.1.3. Data Protection
Parti cipants will be assigned a unique ident ifier by [CONTACT_456]. Any part icipant records ,datasets ,
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any  information thatwould make the participant ident ifiable will not be transferred.
The parti cipant must be inform ed that hi s/her personal  study -related data will be used by  [CONTACT_32855] h local data protecti on law. The l evel of disclosure m ust also b e 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent .
The parti cipant m ust be inform ed that hi s/her m edical  records m ay be examined by [CONTACT_32856] y Assurance auditors or other authorized personnel appo inted by  [CONTACT_456], by  
[CONTACT_6667]/IEC members, and by [CONTACT_32857].
The sponsor has proces ses in place to ensure data protection, informat ion securit y,and data 
integrity.These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data securit y breach.
10.1.4. Dissemination of Clinical Study Data
Commu nication of suspended or terminated dosing
If a decisio n is taken to suspend or terminate dosing in the trial due to safet y findings, this 
decisio n will be communicated by [CONTACT_17083] (for example , through phone and/or 
email) as soon as possible. It will be a requirement that invest igators respond upon receipt to 
confirm that they  understand the communicat ion and have taken the appropriate action prior to 
further dosing any  parti cipants wi th study  intervent ion. Any investigator not responding will be 
followed up by  [CONTACT_32858]. If a dose is planned 
imminent ly, Lilly personnel will immediately, and continually, use all efforts to reach 
investigators until contact [CONTACT_897988] e and instructi ons verified.
Reports
The sponsor will disclose a summary o f study  information, including tabular study results, on 
publicly  available websites where required by  [CONTACT_17087].
Data
The sponsor does not proactively  share data from  Phase 1 clinical trials. Requests for access to 
Phase 1 clinical trial data are evaluated on a case -by-case basis taking into considerat ion the 
abilit y to anonymize the data and the nature of the data collected.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
6810.1.5. Data Quality Assurance
Investigator responsi bilities
All participant data relat ing to the study  will be recorded on printed or eCRF unless transmitted 
to the sponsor or designee electronically  (for exampl e,laboratory  data). The investigator is 
responsible for verifying that data entries are accurat e and correct by  [CONTACT_850989].
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF. Source data may include laboratory  tests, m edical records, and 
clinical not es.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provide direct a ccess to source data documents.
Data monitoring and management
Moni toring details describing strategy  (for example ,risk-based init iatives in operations and 
qualit y such as Risk Management and Mit igation Strategies and Analyt ical Risk-Based 
Moni toring), m ethods, responsibilit ies and requirements, including handling of noncompliance 
issues and monitoring techniques are provi ded in the Moni toring Plan .
The sponsor or designee is responsible for the data management of this study  includin g qualit y 
checking o f the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals ( for example ,
contract resea rch organizations) .
Study  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF by  [CONTACT_32861], com plete, and verifiable fro m source 
docum ents; that the safet y and ri ghts of  parti cipants are being protected; and that the study  is 
being conducted in accordance with the current ly approved protocol and any other study 
agreem ents, ICH GCP, and all applicable regu latory requirements.
Records retention and audits
Records and documents, includin g signed ICFs, pertaining to the conduct of this study  must be 
retained by [CONTACT_897989] a longer retention period. No records may be
destroy ed during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or party  without wri tten notificat ion to the sponsor .
In addit ion, sponsor or its representatives will periodically check a sample of the participant data 
recorded against source documents at the study  site.The study  may be audi ted by [CONTACT_90745], and/or regulatory  agencies at any  time.Investi gators will  be given notice 
before an audit occurs.
Data Ca pture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
69An electronic data capture sy stem  will be used in this study . The si te must define and retain all 
source r ecords and must maintain a record of any data where source data are directly entered into 
the data capture system.
Data collected via the sponsor- provided data capture systems will be stored by [CONTACT_26404]. The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s. Pri or to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically in 
the central  vendor’s database system and reports will be provided to the investigator for review 
and retention. Data will subsequent ly be transferred fro m the central  vendor to the sponsor data 
warehouse.
Data from co mplaint fo rms submitted to the sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.6. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed fro m source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to req uest previous medical records or transfer records, depending on the 
study . Also, current m edical records must be available.
Definit ion of what constitutes source data can be found in Section 10.1.[ADDRESS_1258733] igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by [CONTACT_897990]
failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor ’s procedures, or GCP guidelines
inadequate recrui tment of parti cipants by [CONTACT_093]
discontinuat ion of further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research or ganizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by [CONTACT_897991]  J1X-MC-GZHC (c)
70regul atory  requi rements. The investigator shall prompt ly inform  the parti cipant and shoul d assure 
appropriate participant therapy  and/or foll ow-up.
10.1.8. Publication Policy
In accordance with the sponsor’s publication po licy, the results of this study  will be submitted 
for publicat ion by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.
10.1.9. Long -Term Sample Retention
Sample retenti on enables use of new techno logies, response to regul atory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of 
LY3493269 or after LY3493269 beco mes co mmer cially available.
The fo llowing ta ble lists the maximum retention period for sample ty pes. The retenti on peri od 
begins after the last participant visit for the study .
The m aximum  retent ion times may  be shorter, if specified in local regulat ions and/or if ethical 
review board s/IRBs impose s horter time limits.
Any samples remaining after the specified retent ion peri od will be destroy ed.
The sample retention facilit y will be selected by [CONTACT_3552].
Sample Type Custodian Retention Period after Last Patient Visita
Biomarkers Sponsor or designee 15 years
PK Sponsor or designee 1years
PD Sponsor or designee 1 year
Genetics Sponsor or designee 15 years
Immunogenicity Sponsor or designee 15 years
Abbreviations: PD = pharmacodynamics; PK = pharmacokinetics.
aRetention periods may differ locally.
The sponsor has a right to retain a portion of submitted biopsy  tissue. Archival blo cks will be 
returned to the study  site. Slides and tissue samples collected on study  will not be returned.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
7110.2. Appendix 2: Clinical Laboratory Tes ts
The tests detailed in the Safet y Laboratory  Tests table will be performed by [CONTACT_897992], and at the central  laboratory  for all scheduled assessments from 
Day -3 through the treatment period and fo llow-up.
Protocol -specific require ments for inclusio n or exclusio n of participants are detailed in 
Secti on 5of the protocol.
Addit ional tests (for example, drug/al coho l screen) may be perform ed at any  time during 
the study  as determined necessary  by [CONTACT_897993].
Pregnancy testing will occur as indicated in the SoA.
Invest igators must document their review of each laboratory  safety  report.
Laboratory  and analy te resul ts that coul d unblind the study  will not be reported to invest igat
ive 
sites or other blinded personnel.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
72Safety Laboratory Tests (Screening -Local Laboratory)
Hematology Clinical Chemistry (fasting)
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phosphate
Leukocytes (WBC) Magnesium
Absolute Counts of Creatinine
Neutrophils Glucose (fasting)
Lymphocy tes Urea
Monocytes Total protein
Eosinophils Albumin
Basophils Total bilirubin
Platelets Alkaline phosphatase (ALP)
Aspartate aminotransferase (AST)
Urinalysis Alanine aminotransferase (ALT)
Specific gravity Lipase
pH Amylase
Protein Triglyceride
Glucose Total cholesterol
Ketones HbA1c
Bilirubin Calcitonin
Urobilinogen
Nitrite
Blood Serology
Leukocytes Hepatitis B surface antigena
MicroscopybHepatitis B core antibody, totala
Hepatitis C virus serology ( anti-HCV)a
Follicle -stimulating hormone (FSH)cHuman immunodeficiency virus (HIV)a
Serum p regnancy  test (females only)
Abbreviations: HbA1c = gly cated hemoglobin; RBC = red blood cell; WBC = white blood cell.
aTests may be waived if they have been performed within 6 months before screening with reports available for 
review.
bIf clinically indicated, per investigator’s discretion.
cPerforme d for females at screening, if needed to confirm postmenopausal status.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
73Safety Laboratory Tests (Central Laboratory - from Day -3through Follow -up)
Hematology Clinical Chemistry (fasting)
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phosphate
Leukocytes (WBC) Magnesium
Absolute Counts of Creatinine
Neutrophils Glucose (fasting)
Lymphocy tes Urea
Monocytes Total protein
Eosinophils Albumin
Basophils Total bilirubin
Platelets Alkaline phosphatase (ALP)
Aspartate aminotransferase (AST)
Urinalysis Alanine aminotransferase (ALT)
Specific gravity Lipase
pH Amylase
Protein Triglyceride
Glucose Total cholesterol
Ketones HbA1cc
Bilirubin
Urobilinoge n
Nitrite
Blood
Leukocytes
Microscopya
Pregnancy testb
Tests will be performed at a central laboratory unless otherwise specified.
Abbreviations: HbA1c = gly cated hemoglobin; RBC = red blood cell; WBC = white blood cell.
aIf clinically indicated, per investigator’s discretion.
bLocal laboratory test f or females only: urine pregnancy test at the Day 57 follow -up or early  discontinuation.
cHbA1c samples obtained according to the Schedule of Activities (Section 1.3).
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
7410.2.1. Blood Sampling Summary
Thesetable ssummarize the approximate numbe r of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es, and bioanaly tical assays) during the study .
Blood Sampling Summary Table (Cohorts 1 and 2) 
Purpose Blood Volume 
per Sample (mL)Approximate 
Number of Blood 
SamplesApproximate 
Total Volume 
(mL)
Screening tests (local laboratory)a25 1 25
Clinical laboratory testsa(central laboratory)
HbA1c 3 3 9
Study Visits 10 8 80
Follow -up [ADDRESS_1258734] for cannula patency 0.5 19 9.5
Fasting plasma glucose 2 7 14
6-point glucose 2 30 60
OGTT (central laboratory)
Glucose 2 20 40
Insulin, C-peptide 3 20 60
Glucagon [ADDRESS_1258735] (acetaminophen PK) 2 33 66
Biomarkers (central laboratory)
Lipid panel 
(triglycerides, total cholesterol, low -
density  lipoprotein-cholesterol, very 
low-density  lipoprotein -cholesterol, 
and high -density lipoprotein -
cholesterol )3.5 2 7
Pharmacogenetic sample (stored) 10 1 10
Nonpharmacogenetic sample (stored)
Plasma 2 5 10
Serum 2.5 5 12.5
P800 2 5 10
Immunogenicity 10 4 40
Total 569
Total for clinical purposes (rounded up to the nearest 10 mL) 570
aAdditional samples may be drawn if needed for safety purposes.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
75Blood Sampling Summary Table (Cohorts 3 and 4) 
Purpose Blood Volume 
per Sample (mL)Approximate 
Number of Blood 
SamplesApproximate 
Total Volume 
(mL)
Screening tests (local laboratory)a25 1 25
Clinical laboratory testsa(central laboratory)
HbA1c 3 3 9
Study Visits 10 8 80
Follow -up [ADDRESS_1258736] for cannula patency 0.5 21 10.5
Fasting plasma glucose 2 7 14
6-point glucose 2 30 60
OGTT (central laboratory)
Glucose 2 20 40
Insulin, C-peptide 3 20 60
Glucagon [ADDRESS_1258737] ( acetaminophen PK) 2 33 66
Biomarkers (central laboratory)
Lipid panel 
(triglycerides, total cholesterol, low-
density  lipoprotein-cholesterol, very 
low-density  lipoprotein -cholesterol, 
and high -density lipoprotein -
cholesterol )3.5 2 7
Pharmacogenetic sample (stored) 10 1 10
Nonpharmacogenetic sample (stored)
Plasma 2 5 10
Serum 2.5 5 12.5
P800 2 5 10
Immunogenicity 10 4 40
Total 576
Total for clinical purposes (rounded up to the nearest 10 mL) 580
aAdditional samples may be drawn if needed for safety purposes.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
7610.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a patient or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered 
related to the study  intervent ion.
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of study  intervent ion.
Events Meeting the AE D efinition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments ( for example ,ECG, radi ological scans, vi tal sign 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the invest igator ( that is, not rel ated 
to progression of underlying disease).
Exacerb ation of a chronic or intermittent preexisting condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study  intervent ion administration even 
though it m ay have been present before t he start of the study.
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be r eported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose should be reported regardless of sequelae.
The signs, symptoms, and/or clinical sequelae result ing from lack of efficacy will be 
reported as AE or SAE if they  fulfillthe defini tion of  an AE or SAE. Al so, “lack o f 
efficacy ” or “ failure of expected pharmaco logical acti on”also consti tutes an AE or 
SAE.
Events NOT Meeting the AE D efinition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments thatare associated with the underlying disease, unless judged by [CONTACT_11009]’s condit ion.
The disease/dis order being studi ed or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
77Medical or surgical procedure ( for example ,endoscopy , appendectomy ): the condi tion 
that leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexist ing di sease(s) or condi tion(s) present or 
detected at t he start of the study that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met ( for example ,hospi [INVESTIGATOR_17045]/symptom s of the disease under study , death due t o 
progression of disease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term  “life-threatening” in the definit ion of “serious”refers to an event in which the 
participant was at ri sk of death at the time o f the event. It does not refer to an event, which 
hypotheti cally  might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
In general, hospi[INVESTIGATOR_17046]/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complicat ions that occur during hospi [INVESTIGATOR_446390]. If a complicat ion prol ongs hospi [INVESTIGATOR_17047] f ulfills any  other seri ous cri teria, 
the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE shoul d be considered serious.
Hospi[INVESTIGATOR_5187] a preexist ing condit ion that di d not worsen 
from baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, 
and accidental trauma ( for example ,sprained ankle) thatmay interfere wi th or prev ent 
everyday life functions but do not constitute a substantial disrupt ion.
e.Is a congenital anomaly/birth defect
f.Other situations:
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
78Medical or scient ific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations suc h as important medical events that may not be 
immediately  lifethreatening or result in death or hospi[INVESTIGATOR_17049] m ay requi re medical or surgi cal intervent ion to prevent 1of the other 
outcom es listed in the above defin ition. These events should usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias ,or 
convulsio ns that do not result in h ospi[INVESTIGATOR_3094], or development of drug dependency or 
drug abuse .
10.3.3. Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (for example ,hospi [INVESTIGATOR_1088], l aboratory  reports, and 
diagnosti cs reports) rel ated to the event.
The invest igator will then record all relevant AE/SAE informat ion in the CRF.
It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s me dical  
records to the sponsor or designee in lieu of completion of the AE/SAE CRF page.
There m ay be instances when copi[INVESTIGATOR_17050] s ponsor or desi gnee . In this case, all participant identifiers, with the exc eption of 
the participant number, will be redacted on the copi[INVESTIGATOR_17051] n to the sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical inform ation. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE .
Assessment of Intensity
The invest igator will make an assessment of intensity for each AE and SAE reported during 
the study  and assign it to 1 of the fo llowing categori es:
Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal disco mfort 
and not interfering with everyday act ivities.
Moderate: An even t that causes sufficient discomfort and interferes wit h norm al 
everyday act ivities.
Severe: An event that prevents normal every day activi ties. An AE that is assessed as 
severe should not be confused with a nSAE. Severe is a category  utilized for rating the
intensity of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious”when i t meets at least 1 of the predefined outcomes as 
described in the definit ion of an SAE, NOT when it is rated as severe.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
79Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE.
The invest igator will consider any AEs, SAEs, and clinically important laboratory 
abnorm alities as related to the study  intervention unless there is clear evidence that the 
event i s not rel ated.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal  relati onship of the event to study  intervent ion 
administration will be considered and invest igated.
The invest igator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has 
minimal informat ion to include in the init ial report to the sponsor or designee . 
However, it is very  important that the invest igator always make an assessment of 
causalit y for every  event before the init ial transmission of the SAE data to the sponsor 
or desi gnee .
The invest igator may change his/her opi[INVESTIGATOR_3078] n of caus ality in light of fo llow-up 
inform ation and send a nSAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment i s 1of the cri teria used wh ile determining regulatory  
reporting requirements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by [CONTACT_17098]/or causalit y of the AE or SAE as fully as 
possible . This m ay include addit ional laboratory  tests or invest igations, 
histopathological examinat ions, or consultation with other healt h care professio nals.
If a participant dies during participation in the study or during a recognized fo llow-up 
period,the inv estigator will provide the sponsor or desi gnee with a copy  of any 
post-mortem findi ngs including histopathology .
New or updated informat ion will be recorded in the originally co mpleted CRF.
The invest igator will submit any updated SAE data to the sponsor or desi gnee within 
24 hours of receipt of the information.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
8010.3.4. Reporting of SAEs
SAE Reporting via SAE Report
Facsimile transmissio n of the SAE Report is the preferred method to transmit this 
inform ation to the sponsor or designee .
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE Report within the designated reporting time frames.
Contacts for SAE reporting can be found in SAE Report.
10.3.5. Sponsor Surveillance Process for Dose Escalation or Cohort Expansion
The sponsor has systemat ic and robust internal processes in place that ensure safet y surveillance 
of devel opment com pounds in line wit h the Food and Drug Administration ’s expectati ons for 
safet y assessment committee (SAC) ( FDA Draft Guidance: “ Safet y Assessment for IND Safet y 
Reporting”; FDA Guidance: “Safet y Reporting Requirements for INDs and BA/BE Studies”). 
This includes processes with clearly described roles and responsibilit ies that are owned by  [CONTACT_103] ’s Global Pat ient Safet y organi zation. These processes are designed to monitor the 
evolving safet y profile ( that is, review of cumulat ive SAEs, other important safet y informat ion) 
by [CONTACT_897994] -functional teams in a timely manner at predefined intervals or on an ad hoc 
basis. In addit ion, a dedi cated process m ay be used to perform unblinded comparisons of event 
rates for SAEs as necessary .
This system ensures that the accumulat ing safet y data deri ved from  individual  and mul tiple tri als 
across a development program arereviewed on a regular basis and that important new safet y 
inform ation such as the need for protocol modification or other relevant safety  related materi al is 
ident ified and co mmunicated to regulators and investigators appropriately and in a t imely 
manner .An internal review of aggregate safety  data occurs on at l east a quarterly  basis or m ore 
frequently, as appropriate. Any serious adverse reacti onare reported within the required t imeline 
for expedited reporting.
In addit ion to annual periodic safet y upda tes and to further inform invest igators, a line list ing 
report of suspected unexpected serious adverse reactions is created and distributed to 
investigators on a biannual (twice y early) basis. Any  significant potenti al risk/safety  concerns 
that are being m onitored as well  as any  resul ts being reported i n other peri odic reports for the 
compound; SAC decisio ns; and other significant safet y data (for example, nonclinical, clinical 
findings, removal o f serious adverse react ions) are included in the report.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
8110.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
10.4.1. Definitions
Females of Childbearing Potential
A female is considered fertile fo llowing menarche and until beco ming post -menopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear ( for example ,amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before the first dose of study  intervent ion, additional evaluati on shoul d be 
considered.
Females NOT of Childbearing Potential
Females in the fo llowing categori es are not considered wom en of childbearing potential
1.Prem enarchal
2.Prem enopausal  female wi th 1 of the f ollowing:
docum ented hysterectomy
docum ented bilateral  salpi[INVESTIGATOR_1656]
docum ented bilateral  oophorectomy
For individuals wit h perm anent infert ility due to an alternate medical cause other than the 
above ( for example ,mullerian agenesis, androgen insensit ivity), investi gator di scret ion 
shoul d be applied to determining study  entry .
Note: Documentation can come fro m the site personnel :review of the parti cipant’s m edical 
records, medical examinat ion, or m edical history  interview.
3.Postmenopausal  female is defined as, women with
12 m onths of amenorrhea for women >55 years , with no need for follicle -stimulat ing 
horm one
(FSH)
12 m onths of amenorrh ea for wom en >40 y earswith FSH of ≥40 m IU/mL and no 
other m edical  condi tion such as anorexia nervosa and not taking medications during 
the am enorrhea ( for example, oral contraceptives, hormones, gonadotropin releasing 
horm one, ant i-estrogens, select ive estrogen receptor modulators, or chemotherapy 
that induced amenorrhea )
horm one l evels consistent wi th a pos t-menopausal state per the local laboratory  
reference range
10.4.2. Contraception Guidance
[IP_ADDRESS]. Female Participants
Female participants of childbearing potential are excluded fro m this study .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
8210.4.2.2. Female participants who are not of childbearing potential may participate in this 
study. Male P articipants
Male parti cipants, regardless of their fertili ty status, wi th partners who are nonpregnant women 
of childbearing potential, must agree to either
1.remain abst inent (if this is their preferred and usual lifest yle), or
2.use condoms plus [ADDRESS_1258738] dose of 
study  interventi on.
Male parti cipants shoul d refrain from  sperm  donat ion for the duration of the study plus 105 days, 
which corresponds to approximately 5 mo nths and unt il their plasma concentrations are below 
the level that could re sult in a rel evant potential exposure to a possible fetus.
[IP_ADDRESS]. Contraception Methods
Abstinence
Parti cipants who are abstinent (if this is complete abst inence, as their preferred and usual 
lifest yle) must agree to either remain abst inent without sexual relati onships wi th the opposi te 
sex.
Same -sex relationships
Parti cipants who are in a same -sex rel ationship (as part of their preferred and usual lifest yle) 
must agree to stay  in a same -sex rel ationship without sexual relationships with the opposite sex.
Participants who are in exclusively  same -sex relationships as their preferred and usual lifest yle 
are not required to use contraception.
Highly effective and effective contraception methods
Highly effective methods of contraception (less than 1% failure rate)
Combined oral contraceptive pi[INVESTIGATOR_31076]-pi[INVESTIGATOR_32834] (such as Mirena®and ParaGard®)
NuvaRing®Contraceptive patch –ONLY women less than 198 pounds (90 kg)
Implantable contraceptives Vasectomy –for men in clinical trials
Injectabl e contraceptives (such as Depo -
Provera®)Fallopi[INVESTIGATOR_31077] (Essure®) if confirmed by 
[CONTACT_31084][INVESTIGATOR_32835] (use 2 forms combined except where noted)
Male condom with spermicideaDiaphragm with spermicide
Female condom with spermicideaCervical sponge
Cervical cap with spermicide
aMale and female condoms should not be used in combination.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
83Unacceptable contraception methods
Unacceptable methods of contraception include
periodic abstinence, such as
ocalendar
oovulation
osymptothermal, or
opost-ovulation methods
declaration of abst inence just for the duration of the trial, and
withdrawal .
10.4.3. Collection of Pregnancy Information
Male participants wi th partners who become pregnant
●The invest igator will attempt to collect pregnancy informat ion on any male 
participant’s female partner who beco mes pregnant while the male participant is 
in this study . This applies only  to m ale parti cipants who receive LY3493269.
●After obtaining the ne cessary  signed informed consent from the pregnant female 
partner direct ly, the invest igator will record pregnancy informat ion on the 
appropriate form and submit it to the sponsor within 24 hours of learning of the 
partner’s pregnancy. The female partner wi ll also be fo llowed up to determine the 
outcom e of the pregnancy . Informati on on the status of the mother and child will 
be forwarded to the sponsor. Generally, the fo llow-up will be no longer than [ADDRESS_1258739] imated delivery date. Any te rmination of the pregnancy 
will be reported including fetal status (presence or absence of ano malies) and
indicat ion for the procedure. 
Female participants who become pregnant
●The invest igator will co llect pregnancy information on any female participant
who beco mes pregnant while part icipating in this study .The init ial information 
will be recorded on the appropriate form and submitted to the sponsor within 
24hours of learning of a parti cipant ’s pregnancy . 
●The parti cipant will be fo llowed up to deter mine the outcome of the pregnancy. 
The invest igator will co llect fo llow-up informati on on the parti cipant and the 
neonate and the informat ion will be forwarded to the sponsor. Generally, fo llow-
up will not be required for longer than 6 to 8 weeks beyo nd th e estimated delivery 
date. Any terminat ion of pregnancy will be reported, including fetal status 
(presence or absence of ano malies) or indicat ion for the procedure.
●While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complicat ion or el ective terminat ion of a pregnancy  for medical  reasons will be 
reported as an AE or SAE. 
●A spontaneous abortion (occurring at <2 0weeks gestational age) or still birth 
(occurring at > 20weeks gestational age) is always considered to be an SAE and 
will be reported as such. 
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
84●Any post -study pregnancy -related SAE consi dered reasonably related to the study  
intervent ion by [CONTACT_897995]8.3.[ADDRESS_1258740] igator is not obligated to actively seek this 
inform ation in former study  parti cipants, he or sh e may learn o f an SAE through 
spontaneous reporting.
●Any female part icipant who becomes pregnant while participat ing in the study  
will discont inue study  intervent ion. Thediscont inued participant should follow 
the standard discont inuat ion process and continue direct ly to the fo llow-up phase.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
8510.5. Appendix 5: Genetics
Use/Analysis of DNA
Genet ic variat ion may impact a participant’s response to study  intervent ion, suscept ibilit y to, and 
severit y and progressi on of  disease. Vari able response to study  intervent ion may be due to 
genet ic determinants that impact drug absorption, distribut ion, metabo lism, and excretion; 
mechanism o f action of  the drug; di sease et iology; and/or m olecular subt ype of the disease being
treated. Therefore, where local regulat ions and IRB/IEC allow, a blood sample will be co llected 
for DNA analysis fro m consenting part icipants.
DNA samples will be used for research related to the drug target and mechanism o f action of  
LY3493269 or diabete s, obesit y, and di abetic co mplicat ions including NASH and related 
diseases. They  may also be used to develop tests/assays including diagnost ic tests related to 
LY3493269 and interventions of this drug class and diabetes, obesit y, and di abetic com plicat ions
including NASH. Genet ic research may consist of the analysis o f 1or more candi date genes or 
the analysis o f genetic m arkers throughout the genome or analysis o f the ent ire geno me (as 
appropriate).
Addit ional analyses m ay be conducted if it is hypothesize d that thi s may  help further understand 
the clinical data.
The samples may  be analyzed as part of a mult i-study  assessment of genetic factors involved in 
the response to LY3493269 or study  intervent ions of this class to understand study  disease or 
related condi tions.
The results of genet ic analyses may be reported in the clinical study  report or in a separate study  
summary.
The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confident iality.
The samples will be retained while research on LY3493269, similar study  intervent ions of this 
class, or di abetes, obesi ty, and di abetic co mplications including NASH cont inues but no l onger 
than 15 y ears or other period as per local requirements.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
8610.6. Appendix 6: Liver Safety: S uggested Actions and Follow -up 
Assessments
See Secti on [IP_ADDRESS] for guidance on appropri ate test sel ection.
The sponsor -designated central  laboratory  must complete the analysis of all selected testing 
except for microbio logy testing.
Local  testing m ay be performed in addit ion to central testing when necessary for immediate 
participant m anagement.
Results will be reported if a validated test or calculati on is available.
Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -red blood cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
  Neutrophils, segmented Gamma -glutamyl transferase (GGT)
  Lymphocytes Creatine kinase (CK)
  Monocytes Other Chemistry
  Basophils Acetaminophen
  Eosinophils Acetaminophen protein adducts
Platelets Alkaline phospha tase isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
Coagulation Copper
Prothrombin time, INR (PT -INR) Ethyl alcohol (EtOH)
Serology Haptoglobin
Hepatitis A virus (HAV) testing: IgA (quantitative)
  HAV total antibody IgG (quantitative)
  HAV IgM antibody IgM (quantitative)
Hepatis B virus (HBV) testing: Phosphatidylethanol (PEth)
  Hepatitis B surface antigen (HBsAg) Urine Chemistry
  Hepatitis B surface antibody (anti -HBs) Drug screen
  Hepatitis B core total antibody (anti -HBc) Ethyl glucuronide (EtG)
  Hepatitis B core IgM antibody Other Serology
  Hepatitis B core IgG antibody Anti- nuclear antibody (ANA)
  HBV DNAbAnti-smooth muscle antibody (ASMA)a
Hepatis C virus (HCV) testing: Anti- actin antibodyc
  HCV antibody Epstein -Barr virus (EBV) testing:
  HCV RNAb  EBV antibody
Hepatitis D virus (HDV) testing:   EBV DNAb
  HDV antibody Cytomegalovirus (CMV) testing:
Hepatitis E virus (HEV) testing:   CMV antibody
  HEV IgG antibody   CMV DNAb
  HEV IgM antibody Herpes simplex virus (HSV) testing:
  HEV RNAb  HSV (Type 1 and 2) antibody
Microbiologyd  HSV (Type 1 and 2) DNAb
Culture: Liver kidney microsomal type 1 (LKM -1) antibody
  Blood
  Urine
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
87Abbreviations: Ig = immunoglobulin ; INR = international normalization ratio; PT = prothrombin time .
aNot required if anti -actin antibody is tested.
bReflex/confirmation dependent on regulatory requirements, testing availability, or both.
cNot required if anti -smooth muscle antibody (ASMA) is tested.
dAssay ed ONLY by [CONTACT_897996] r-designated local laboratory; no central testing available.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
8810.7. Appendix 7: Pancreatic Monitoring
Glucagon -like peptide [ADDRESS_1258741] been associated with a possible risk of acute pancreat itis. 
In 2006, the US prescribing informat ion for exenatide was revised to include the event of 
pancreat itis. In 2007, the US prescribing informat ion for this medicat ion was amended to include 
pancreat itis under “Precaut ions”. Epi [INVESTIGATOR_897973] T2DM.
To enhance understanding of the natural variability o f pancreat ic enzymes in the T2DM 
popul ation and, to assess for any  potenti al effects of LY3493269 on the exocrine pancreas, 
amylase ,and lipase values will be mo nitored in all current and future clinical trials wit h 
LY3493269.
Addit ional monitoring will be requested for amylase or lipase values ≥3X the ULN at any  visit 
after randomizat ion, even in asymptomatic participants ( see the following figure ). Lipase and 
amylas e may also be obtained at any  time during the clinical trials for any  parti cipant suspected 
of having symptom s suggest ive of pancreat itis (such as severe GI signs and/or symptoms), at the 
investigator’s discret ion.
Acute pancreat itis is an AE defined as an acute i nflammatory  process of the pancreas that may 
also invo lve peripancreatic tissues and/or remote organ systems. The diagnosis of acute 
pancreat itis requires 2 of the fo llowing 3 features:
abdo minal pain characteristic of acute pancreatit is
serum  amyl ase and/or lipase >3X ULN
characterist ic findings of acute pancreat itis on the CTscan or MRI
Most participants with acute pancreat itis experience abdo minal pain that is located generally in 
the epi [INVESTIGATOR_897974] -half of the cases. The pain is often 
associ ated wi th nausea and vo miting. However, experience wit h GLP -1 agoni sts has 
demonstrated that som e parti cipants asymptomat ic for classic pancreat itis may demo nstrate 
significant el evations of lipase and/or amylase. Fo r participants considered by [CONTACT_133668], but whose value(s) for lipase and/or amylase are ≥3X ULN, an 
algorithm is in place to fo llow these parti cipants safely  and to qui ckly reach (or not reach) a 
diagnosis of pancre atitis.
Parti cipants diagnosed wi th pancreat itis will be discontinued fro m the study . Invest igators will 
be responsible for fo llowing, through an appropriate healt h care option, these pancreat itis AEs 
until the events resolve or are explained. Adverse even ts that meet the di agnosti c criteria of acute 
pancreat itis will be captured as SAEs. For all other pancreat ic AEs (such as idiopathic or 
asymptomat ic pancreat ic enzyme abnormalit ies), the invest igator will be responsible for 
determining the seriousness of the event (AE or SAE) and the relatedness of the event to 
investigat ional product .
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
89Abbreviations: CT = computed tomography; MRI = magnetic resonance imaging; ULN = upper limit of normal.

CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
9010.8. Appendix 8: Hypersensitivity Event Tests
This table list sthe recommended tests that should be obtained in case of a clinically significant 
hypersensit ivity/allergy event. Selected tests may be obtained in the event of anaphylaxis or 
generalized urticaria.
Anti-LY antibodies (immunogenicity) Tryptase
LY concentration (PK) N-methylhistamine
Drug -specific IgEa
Basophil Activation Testa
Complements
Cytokine Panel
Abbreviations: Ig = immunoglobulin; LY = LY3493269; PK = pharmacokinetics.
aBasophil Activation test will be performed if a drug -specific IgE assay is unavailable.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
9110.9. Appendix 9: Abbreviations
Term Definition
ADA antidrug antibody
AE adverse event: Any untoward medical occurrence in a patient or clinical investigation 
participant administered a pharmaceutical product that does not necessarily have a 
causal relationship with this treatment. An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the concentration versus time curve
BG blood glucose
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the participant is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and theparticipant are not.
A double -blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the subjects 
are aware of the treatment received.
CFR Code of Federal Regulations
CI confidence interval
Cmaxmaximum observed drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRF case report form
CRP clinical research physician: Individual responsible for the medical conduct of the study.
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, g lobal safety physician ,or other medical officer.
CSE clinically  significant events
CT computed tomography
CV cardiovascular
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
92ECG electrocardiogram
eCRF electronic case report form
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
FSH follicle -stimulating hormone
GCP good clinical practice
GI gastrointestinal
GIP glucose - dependent insulinotropic polypeptide
GLP-[ADDRESS_1258742]
HbA1c glycated hemoglobin
HIV human immunodeficiency virus
HR heart rate
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC independent ethics committee
informed consent A process by [CONTACT_9444] a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate. Informed consent is 
documented by [CONTACT_3553] a written, signed ,and dated informed consent form .
INR internatio nal no rmalized ratio
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/lock ed.
investigator A person responsible for the conduct of the clinical study at a study site. If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible 
leader of the team and may be called the principal investigator.
IRB institutional review board
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
93IWRS interactive web -response sy stem
MRI magnetic resonance imaging
NASH nonalcoholic steatohepatitis
NOAEL no-observed -adverse -effect level
OGTT oral glucose tolerance test
OTC over the counter
p-amylase pancreatic amylase
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control
PD pharmacodynamics
PG plasma glucose
PK pharmacokinetics
PR pulse rate
randomize the process of assigning participants to an experimental group on a random basis
QTcF QT interval corrected using Fridericia’s formula
QW once weekly
SAC safety assessment committee
SAD single -
ascending dose
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SoA Schedule of Activities
study intervention A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different fro m the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
TBL total bilirubin
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
94T2DM type 2 diabetes mellitus
TE-ADA treatment -emergent -antidrug antibo dy
TEAE treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relatio nship 
with this treatment.
tmaxtime of maximum observed drug concentration
ULN upper limit of normal
VAS visual analog scale
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
9510.10. Appendix 10: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment [a]: 11
-July-2020
This amendment is considered to be substant ial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union .
Overall Rationale for the Amendment:
Section # and 
NameDescription of Change Brief Rationale
1.3 Schedule of 
ActivitiesFor Cohorts 3 and 4, the following timepoints were added:
Visits on Days 9 and 16,
Drug/alcohol screen on Days 8 and 15,
Triplicate ECGs and vital signs at 1, 4, 6, and [ADDRESS_1258743] dose on Days 8 and 15, at 24 hours postdose on 
Days 9 and 16, and at 1 and 4 hours postdose on Day 
22, and
Pharmacokinetic samples at [ADDRESS_1258744].Original table revised 
for clarity.
4.3 Justification 
of DoseIn Table 3, an error in the human maximum dose (mg/kg) 
was corrected from 0.556 to 0.0556.  Based on feedback 
from the FDA.
5.1 Inclusion 
CriteriaUpper age limit for participants reduced to 65 years. Based on feedback 
from the FDA.
6.6.2 Dose -
Escalation 
Stoppi[INVESTIGATOR_897975]:  
Three or more participants at the same dose level 
experience drug -related GI effects causing severe distress 
and/or clinically significant cardiovascular AE deemed 
related to LY3493269 administration. Based o n feedback 
from the FDA.
7.1.2 Persistent 
Hyperglycemia/ 
HypoglycemiaAdded details on the number and duration of hypoglycemic 
events to be considered for discontinuation of study 
intervention.Based on feedback 
from the FDA.
8.9 
Immunogenicity 
AssessmentsRemoved that ADA cross -reactively binds to native GIP ad 
GLP -1 would necessitate additional ADA samples Based on feedback 
from the FDA.
[IP_ADDRESS] Female 
participantsRemoved the contraception restriction for female 
participants not of childbea ring potential.These restrictions did 
not provide the 
participant with any 
additional safety 
benefit.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
96Amendment [b]: 13-October -2020
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n. 
Overall Rationale for the Amendment:
Thisamendment serves to clarify that dose escalation between cohorts will be based on a review 
of 2-week safet y and tol erabili ty data f rom parti cipants who received LY3493269 through Day  
15 at the preceding lower dose.
Section # and 
NameDescription of Change Brief Rationale
1.2.Schema Diagram  was updated to reflect 
data reviews for dose -escalat ion 
decisio ns.
4.2. Scientific 
Rationale for 
Study  DesignText updated to allow “up to 2” 
from “2”participants to be assigned 
to dul aglut ide or placebo treatment
per cohort.
Deleted the redund ant text “The 
decisio n to escalate doses between 
and wit hin the cohorts will be based 
primarily on safet y and tolerabilit y 
data from  preceding dose cohorts 
and wit hin the cohort”. This text 
was reported in Sect ion 6.6.1.Editorial change to align with 
intended co mpletion of 
“approximately” 12 evaluable 
participants in each cohort.
5.1. Inclusio n 
CriteriaUpper age limit for participants 
revised to 70 y ears.The protocol is amended to 
increase the age limit to 70 years 
for the fo llowing reasons: 
(1) No relevant differences with 
regard to safet y between 
individuals aged <65years and 
those >[ADDRESS_1258745] been observed 
with incret in agents
(Boustani etal. 2016, 
Warren etal.2018);
(2) One commo n concern in elderly 
popul ation is the risk of severe 
hypogly cemia (Warren etal.2018) ; 
(3) Severe hy poglycemia occurs 
rarely  with incretin therapy  
as these 
agents are not insulin 
secretagogues;
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
97Section # and 
NameDescription of Change Brief Rationale
(4) There were no events of severe 
hypoglycemia after single dose of 
LY3493269 in healt hy part icipants;
(5) To enable en rolment during the 
current COVID -19 pandemic ;
(6) To allow for a broader 
popul ation to be safely studied.
6.6.1. Dose 
Escal ationText updated to describe dose -
escalat ion decisio ns between 
successive cohorts, which would be 
based on data from preceding 
doses.
Clarified l anguage describing dose 
adjustm ents f or parti cipants wi th 
tolerabilit y issues after dose 
escalat ions wit hin Cohorts 3 and 4.Dose escalat ions between 
successive dose levels are based on 
data from  preceding l ower doses, 
and not “cohorts”.
Dose adjust ments will be based on 
individual pat ient-level safet y and 
tolerabilit y data.  
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
9811. References
[ADA ] American Diabetes Associat ion.Glycemic targets: standards of medical care in diabetes -
2019. Diabetes Care .2019;42(Suppl 1):S61– S70.
Banks PA, Freeman ML; Practice Parameters Committee of the American Co llege of 
Gastroenterology . Practi ce gui delines in acute pancreatit is. Am J Gastroenterol. 
2006;101(10):2379 -2400
Boustani , M. A., Pi [INVESTIGATOR_897976], I., Yu, M., Thieu, V. T., Varnado, O. J., & Juneja, R. (2016). 
Similar efficacy and safet y of once ‐weekly dulagluti de in pat ients with type 2 di abetes aged≥ 
65 and< 65 y ears. Diabetes, Obesit y and Metabolism, 18(8), 820 -828.
Campbell JE, Drucker DJ. Pharmacology , physi ology , and mechanisms o f incretin hormone
action. Cell Metab . 2013;17(6):[ADDRESS_1258746] for the treatment of ty pe 2 di abetes m ellitus: f rom discovery  to clinical  proof  of 
concept. Mol Metab . 2018;18:3 -14.
Danne T, Phil otheou A, Gol dman D, et al . A randomized trial co mpar ing the rate of 
hypoglycemia –assessed using continuous glucose monitoring –in 125 preschool children 
with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study ). 
Pediatr Diabetes . 2013;14(8):593 -601. Erratum in: Pediatr Diabetes . 2015;16(6):462.
Flint A, Raben A, Blundell JE, Astrup A. Reproducibilit y, power and validit y of visual  anal ogue 
scales in assessment of appetite sensat ions in single test meal studies. Int J Obes . 
2000;24(1):[ADDRESS_1258747], in pat ients with type 2 di abetes: a randomised, placebo -controlled and 
active co mparator -controlled phase 2 trial. Lancet . 2018;392([ZIP_CODE]):2180-2193.
Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota 
M, Kimura Y, [COMPANY_005] K, Isaji S, Otsuki M, Matsuno S. JPN guidelines for the management of 
acute pancreatit is: diagnostic criteria for ac ute pancreatit is. JHepatobiliary Pancreat Surg . 
2006;13(1):25 -32
Lorenz M, Lawson F, Owens D, et al. Different ial effects of glucagon ‑like pepti de‑1 receptor 
agonists on heart rate. Cardiovasc Diabetol . 2017;16:6.
Trulicit y [package insert]. Indi anapo lis,IN: Eli Lilly and Co.; 2019.
van Ca n J, Sl oth B, Jensen CB, et al. Effects of the once -daily GLP -1 analog liraglut ide on 
gastri c empt ying, glycemic parameters, appetite and energy metabo lism in obese, non -diabet ic 
adults. Int J Obes . 2014;38(6):784 -793.
Warren, M., Chay kin, L., Trachtenbarg, D., Nay ak, G., Wijayasinghe, N., & Cariou, B. (2018). 
Semaglut ide as a therapeutic option for elderly pat ients with type 2 diabetes: Pooled analysis 
of the SUSTAIN 1 ‐5 trials. Diabetes, Obesit y and Metabo lism, 20(9), 2291- 2297.
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequent ly repeated glucose measurements 
overestimate the incidence of inpatient hy poglycemia and severe hyperglycemia. J Diabetes 
Sci Technol . 2010;4(3):577 -582.
CONFIDENTIAL Protocol  J1X-MC-GZHC (c)
99Young A. Inhibit ion of gastri c em ptying. Adv Pharmacol . 2005;52:99-121.
L e o  D o c u m e n t  I D  =  7 1 f 3 8 8 6 3 - d 5 2 3 - 4 2 4 2 - b a b b - c 9 3 0 7 3 2 3 a b 0 7 
A p p r o v e r : 
A p p r o v a l  D a t e  &  T i m e :  1 6 - J u l - 2 0 2 1  1 5 : 0 9 : 5 4  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 6 - J u l - 2 0 2 1  1 7 : 0 9 : 5 7  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 